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Abstract 
Aberrant neuron-glia interactions can contribute to a variety of neurodegenerative diseases.  
We have previously demonstrated that enhanced activation of Erb B2, which is a member of the 
epidermal growth factor receptor (EGFR) family, can contribute to the development of diabetic 
peripheral neuropathy (DPN).  In peripheral nerves, Erb B receptors are activated by various 
members of the neuregulin-1 (NRG1) family including NRG1 Type I, NRG1 Type II and NRG1 
Type III to regulate Schwann cell growth, migration, differentiation and dedifferentiation.  
Alternatively, Erb B2 activity can be negatively regulated by association with the Erb B2-
interacting protein, erbin.  Since the effect of diabetes on the expression of NRG1 isoforms and 
erbin in peripheral nerve are unknown, the current study determined whether changes in NRG1 
isoforms and erbin may be associated with altered Erb B2 signaling in DPN.  Swiss Webster 
mice were rendered diabetic with streptozotocin (STZ) and after 12 weeks of diabetes, treated 
with erlotinib, an inhibitor of Erb B2 activation.  Inhibition of Erb B2 signaling partially reversed 
several pathophysiologic aspects of DPN including a pronounced sensory hypoalgesia, nerve 
conduction velocity deficits and the decrease in epidermal nerve fiber innervation.  We also 
observed a decrease of NRG1 Type III but an increase of NRG1 Type I level in diabetic sural 
nerves at early stage of diabetes.  With disease progression, we detected reduced erbin 
expression and enhanced MAPK pathway activity in diabetic mice.  Pharmacologic inhibition of 
Erb B2 suppressed MAPK activity in diabetic sural nerves.  These results support that 
hyperglycemia may impair NRG1-Erb B2 signaling by disrupting the balance between NRG1 
isoforms, decreasing the expression of erbin and correspondingly activating the MAPK pathway.  
Together, imbalanced NRG1 isoforms and downregulated erbin may contribute to the 
dysregulation of Erb B2 signaling in the development of DPN. 
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Chapter 1: Introduction 
1.1. Overview of Diabetes Mellitus  
1.1.1. Diabetes Mellitus 
Diabetes Mellitus is a metabolic disorder characterized by chronic hyperglycemia and 
impaired metabolism of carbohydrate, fat and protein, which result from deficiency in insulin 
secretion, sensitivity and action.  It is the fastest growing non-communicable disease in the world 
and gives rise to microvascular abnormalities and complications (retinopathy, nephropathy and 
neuropathy) [1-3]. 
Diabetes imposes remarkably high human, social and economic impacts worldwide.  
According to the sixth edition of the International Diabetes Federation (IDF) Diabetes Atlas [4], 
382 million people currently are living with diabetes, about 8.3% of the global population.  
Among them, 175 million cases are undiagnosed.  Considering the additional 316 million people 
with impaired glucose tolerance (IGT), the diabetic population is estimated to reach 592 million 
in 2035 if the trend continues.  Diabetes and its complication make patients as twice as likely to 
die early compared to non-diabetic individuals.  Globally, 5.1 million death cases were caused by 
diabetes directly or indirectly. 
In the United States, 25.8 million people have diabetes including 7.0 million undiagnosed 
patients in 2011 [5].  10.9 Million of these individuals, about 26.9%, are 65 years old or older.  
Every year, diabetes induces more death cases in the U.S. than AIDS and breast cancer 
combined, making it the 7th leading cause of death. 
Unfortunately, 80% of the diabetic population are concentrated in low- and middle-income 
regions, especially emerging hotspots, such as the Middle East, the Western Pacific archipelago, 
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sub-Saharan Africa and South-East Asia.  Though the Africa region has the smallest population 
of diabetes (19.8 million) currently, it may reach 41.4 million in 2035, increasing 109.1%.  The 
high increase predicted in this region is mostly attributed to rapid economic development and 
population growth without adequate healthcare.  In 2013, 548 billion USD (increased from 465 
billion in 2011) in healthcare expenditures were diabetes-related, accounting for 11% of the total 
healthcare cost worldwide.  However, nearly half of this was accounted by healthcare costs in the 
United States (263 billion), followed by Europe (147 billion); less than 1% was spent by South-
East Asia and Africa combined [4]. 
1.1.2. Diagnostic Criteria of Diabetes Mellitus 
Since 1965, the World Health Organization (WHO) has published guidelines for the 
diagnosis and classification of diabetes.  Table 1.1.2.1 summarizes the 1999 [1] and 2006 
recommendations [6].  Plasma glucose concentration is the basis for diagnosis.  However, 
considering the availability of equipment and cost-efficiency, whole blood samples could also be 
used in the diagnosis.  However, the glucose concentration is 10-15% higher in plasma or serum 
samples compared to whole blood samples [7]. 
3 
 
Table 1.1.2.1: Diagnosis Criteria for Diabetes Mellitus 
 
The two main methods used to render a diabetes diagnosis are fasting blood glucose (FBG) 
and the oral glucose tolerance test (OGTT).  FBG measures the plasma glucose level in a person 
who has been fasting for at least 8 hours and is more convenient and cost-efficient compared to 
an OGTT, although the latter has been shown to be more accurate [8].  An OGTT indicates the 
action of insulin on promoting glucose uptake and measures the blood glucose level during a 2-
hour period after ingesting a 75 g glucose load.  The OGTT is always performed after at least an 
8-hour fast.  The euglycemic hyperinsulinemic clamp and the hyperglycemic clamp are tests for 
insulin sensitivity and β-cell function, respectively.  These tests represent the gold standard for 
accessing first- and second-phase of glucose-stimulated insulin secretion.  Since the first-phase 
insulin response is absence in all diabetic patients whose FBG levels exceed 115 mg/dL, glucose 
tolerance test could not quantify the β-cell function in overt diabetes [9].  In 2009, an 
International Committee [10] and the American Diabetes Association (ADA) recommended 
glycated hemoglobin (HbA1c) measurement as an additional means to diagnose diabetes.  A 
Plasma
Venous Capillary Venous
Diabetes Mellitus
Fasting and/or ≥6.1 (≥110) ≥6.1 (≥110) ≥7.0 (≥126)
2-hr post glucose load ≥10 (≥180) ≥11.1 (≥200) ≥11.1 (≥200)
Impaired Glucose Tolerance (IGT)
Fasting (if measured) and <6.1 (<110) and <6.1 (<110) and <7.0 (<126) and
2-hr post glucose load ≥6.7 (≥120) ≥7.8 (≥140)
≥7.8 (≥140) and 
<11.1 (<200)
Impaired Fasting Glycemia (IFG)
Fasting and
≥5.6 (≥100) and 
<6.1 (<110)
≥5.6 (≥100) and <6.1 
(<110)
≥6.1 (≥110) and 
<7.0 (<126)
(if measured) 2-hr post glucose load <6.7 (<120) <7.8 (<140) <7.8 (<140)
Glucose concentration, mmol l-1 (mg dl-1)
Whole Blood
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measurement of HbA1c higher than 6.5 percent is regarded as diabetes.  However, the special 
equipment requirement and higher cost limits extensive use of this technique by individuals. 
An underlying principle of these new criteria is that diagnosis of diabetes should never 
depend on only a single abnormal blood glucose value.  At least one additional positive glucose 
test result is required to confirm diabetes.  Thus, periodic re-testing is advised for pre-diabetic 
patients, who have IGT or IFG.  In addition, physicians should take ethnicity, family history, 
age, and other health issues into consideration [1]. 
1.1.3. Classification and Clinical Features of Diabetes Mellitus 
In 1922, the Canadian scientist Frederick Banting and his medical student Charles Best 
successfully isolated insulin from dog pancreas.  Administration of this pancreatic extract to a 
14-year old boy named Leonard Thompson dramatically improved his diabetic condition.  Since 
this breakthrough, insulin therapy has become the definitive treatment for diabetes, especially in 
the cases of complete loss of β-cell mass.  Historically, diabetes was classified based on the 
dependence of insulin treatment.  This gave rise to two sub-types of diabetes (insulin-dependent 
diabetes and non-insulin-dependent diabetes).  However, in 1999, the WHO recommended a new 
etiological classification based on our improved understandings of the causes of diabetes as non-
insulin-dependent diabetes can evolve to an insulin-dependent diabetes [1, 6].  This new 
classification includes Type 1 (mostly autoimmune diabetic cases), Type 2 (marked by insulin 
resistance and obesity-related), gestational diabetes and other sub-types related to mutations in 
genes affecting insulin production and glucose metabolism. 
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Type 1 Diabetes Mellitus 
Type 1 Diabetes Mellitus (T1DM) accounts for less than 5% of total diabetic cases but the 
population continues to increase.  Among those, 90% of T1DM cases are attributable to an 
autoimmune process, while the remaining cases have no clear evidence of autoimmunity 
(idiopathic diabetes).  The latter situation is common in African and Asian individuals.  All Type 
1 diabetic patients are prone to ketoacidosis and β-cell destruction [1, 7].  Usually, the 
destruction of β-cell progresses rapidly, resulting in early and severe onset of diabetes in 
children.  However, this process can manifest in adults, in which cases it is referred as latent 
autoimmune diabetes in adults (LADA).  Since lack of insulin considerably disrupts energy 
metabolism and glucose homeostasis, polyuria (increased urination), polydipsia (extremely 
thirsty) and weight loss are three common clinical features of T1DM.  Diabetic ketoacidosis may 
be present acutely or become the first manifestation that leads to a diagnosis of T1DM.  Without 
early diagnosis and proper intervention, diabetic ketoacidosis can cause coma and even death, 
accounting for 5% mortality [7]. 
Insulitis and β-cell destruction are pathogenic hallmarks of T1DM.  The initial step of T1DM 
progression (Checkpoint 1) is the infiltration of T lymphocytes and macrophages into islets in 
response to specific Human leukocyte antigen (HLA) presented on β-cells [11, 12].  Activated T 
cells (CD4+ and CD8+ T cells) and macrophages then release several pro-inflammatory 
cytokines, such as interleukin-1β (IL-1β), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-
α) [13-16].  These cytokines activate their cognate receptors on islet cells and induce several 
signaling pathways, such as nuclear factor kappa B (NF- κB) and inducible nitric oxide synthase 
(iNOS), resulting in production of nitric oxide (NO) [17, 18].  The iNOS in human pancreatic 
islets can only be induced by NF- κB activation via a combination of two or three types of 
6 
 
cytokines, suggesting potential defense mechanisms may exist to protect β-cells if only a single 
type of cytokine is present.  A high concentration of cytokine-induced release of oxygen free 
radicals and NO production could suppress glucose-stimulated insulin secretion (GSIS) and 
eventually lead to β-cell apoptosis [19].  In addition, studies have shown that there are other 
pathways involved in cytokine-induced β-cell apoptosis, such as activation of members of the 
mitogen-activated protein kinase (MAPK) family [20].  All three sub-types of the MAPK family 
(extracellular signal regulated kinases (ERK or p42/p44 MAPK), c-Jun NH2-terminal kinase 
(JNK), and p38 MAPK) were activated in rat islets, correlating with IL-1β-induced NO 
production.  Interestingly, inhibition of the JNK pathway, but not ERK or p38, prevented NO-
induced β-cell death [21]. 
In order to increase β-cell mass for insulin demand in response to inflammation and oxidative 
stress, β-cells acutely proliferate either by self-replication [22] or by transforming from α-cells 
[23].  However, with a slow turnover rate, even proliferation of β-cells cannot compensate for the 
destruction and viability loss induced by long-term exposure to hyperglycemia and oxidative 
stress.  Complete failure of β-cell self-regulation is regarded as the final checkpoint for the onset 
of T1DM [24]. 
Given the early onset and rapid progression of T1DM, validated predictive biomarkers are 
well-studied for diagnosis and risk estimation.  However, not all biomarkers reflect the 
underlying pathogenesis of T1DM, since the analysis from family cases of T1DM does not find a 
consistent positive prevalence of autoimmunity for CD4+ and CD8+ T cells [24].  Certain HLA 
molecules presenting on islet β-cells are recognized by T lymphocytes and lead to T cell 
infiltration into peripheral islets, which is the primary feature of disease progression.  Certain 
HLA class II alleles at the HLA DR and HLA DQ loci will increase the risk of inherited T1DM 
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up to 30% in a child with a family history, especially those carrying the HLA DRB1*03,*04; 
DQB1*0302 genotype [25].  Interestingly, some protective HLA DQB, such as HLA DQB1*0602 
could independently lower the risk estimation.  After confirming the genetic risk with or without 
family history, autoantibody testing is usually performed.  Currently, insulin or proinsulin, 
GAD65 or GAD67, IA-2 (or ICA512 or IA-2β or PHOGRIN), and ZnT8 are four major islet 
antigens tested for routinely [26].  Islet autoantibodies are rarely detectable before 6 months of 
age but show a peak incidence at around 1 to 2-year old [27], which correlates with the time-
course of β-cell destruction.  Thus, early biomarker detection and consideration of the 
differences in the immune system in infants and older children may provide a preventive strategy 
before β-cell loss. 
Usually, antibodies with specificity to insulin or proinsulin, whose occurrence is associated 
with the HLA DRB1*04; DQB1*0302 alleles, appear first, while the detection of antibodies to 
IA-2 (or ICA512 or IA-2β or PHOGRIN) have the highest risk of diabetes.  With disease 
progression, multiple autoantibodies to islet proteins may be detected.  Direct measurement of β-
cell function is advised in individuals with multiple positive islet autoantibodies.  Unfortunately,  
no clear triggers have been determined to the onset of T1DM [28].  Indeed, based on the 
variability in the age of diagnosis and progression rate between individuals, environmental 
factors such as nutrition, birth weight, birth oxygen level and maternal condition likely influence 
the onset and progression of T1DM.  Detailed genetic analysis may give patients a more accurate 
assessment of their risk for developing T1DM, but how this information may be used clinically 
to delay the onset of T1DM is unclear. 
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Type 2 Diabetes Mellitus 
 Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of the diabetic cases.  In 
contrast to the early onset and presence of ketoacidosis in T1DM, T2DM can be asymptomatic 
for several years before diagnosis.  As such, substantial proportion of T2DM cases have already 
developed microvascular complications.  It is often the symptoms of the complications that drive 
the visit to the physician to yield the diagnosis of T2DM.  The WHO and IDF recommend 
screening for T2DM on a routine basis [29], especially for those with risk factors, such as 
overweight/obesity, family history, cardiovascular conditions, history of gestational diabetes and 
drug use [30].  After identifying high risk individuals through Risk Assessment Questionnaires, 
biochemical tests are performed to measure random blood or urine glucose, HbA1c, or blood 
pressure and cholesterol levels.  Diagnostic tests (FBG and/or OGTT) and intervention are 
warranted after positive screening tests [29, 30]. 
T2DM is clinically characterized by insulin resistance due to impaired insulin secretion or 
action, elevated glucagon and eventual β-cell dysfunction [7].  Glucagon is secreted from islet α-
cells and an inability of insulin to suppress glucagon secretion is a hallmark of the overall 
metabolic stress in T2DM.  T2DM is usually caused by a combination of genetic and 
environmental factors.  Though mutations in insulin receptors [31, 32], the insulin-sensitive 
glucose transporter (GLUT)-4 [33] and a zinc transporter (SLC30A8 encoded) exclusively 
expressed on insulin secretory vesicles [34] have been detected in certain sub-groups of Type 2 
diabetic patients, no common mutations have been identified across the larger population of 
Type 2 diabetics.  Therefore, unlike T1DM, environmental factors play a predominant role in the 
development of T2DM. 
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Aging is a natural process that decreases insulin sensitivity due to changes in body 
composition and physical activity.  The ADA recommends screening every 3 years starting at 45 
years of age if no other risk factors are identified [35].  Gestational diabetes and low birth weight 
also have been linked to IGT and T2DM development later in the lives of both mothers and 
children [36, 37].  Infants with poor intrauterine nutrition and impaired growth during early life 
showed higher blood pressure but lower weight at 1 year old, which could strongly affect β-cell 
development. 
The most important and common risk factor of T2DM is overweight/obesity, which is 
defined as abnormal or excessive fat accumulation that may harm health.  A body mass index 
(BMI) measurement of more than 25 is regarded as overweight, and a BMI of 30 or greater 
defines clinically obese.  In 2008, more than 1.4 billion adults (20 and older) were overweight, 
and over 500 million were obese.  The onset age of overweight/obesity has moved down into 
younger adults in recent years and more than 40 million children under the age of five were 
overweight in 2011 [38]. 
As elevated glucose levels persist in patients with IGT or T2DM, “glucotoxicity” is 
considered the primary contributor to the development of insulin resistance [39].  High glucose 
concentration progressively compromises insulin gene expression, insulin secretion and GSIS in 
cell lines [40], isolated islets [41] and animals [42].  Due to the tight correlation of obesity and 
T2DM, the concept of “lipotoxicity” [43] or “glucolipotoxicity” [44] has also been proposed for 
promoting insulin resistance and T2DM. 
Lipotoxicity might be a secondary phenomenon after the onset of hyperglycemia [45].  In 
obese individuals, plasma levels and turnover rates of free fatty acids (FFAs) are increased 
compared with lean individuals [7].  Long-term exposure to FFA could increase basal insulin 
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secretion but inhibit GSIS in both animal models [43, 46, 47] and humans [48].  Meanwhile, high 
FFA concentrations could not only affect insulin secretion, but also impair insulin action and 
induce insulin resistance in muscle [49] and liver [50].  Increased FFA oxidation competes with 
glucose oxidation, resulting in suppressed glycogen synthesis [51] and accelerated 
gluconeogenesis [52].  FFA can eventually induce β-cell apoptosis in the presence of high 
glucose [53].  Therefore, the therapeutic indication for “glucolipotoxicity” would be tight control 
of blood glucose levels in the early stages of diabetes, which might be sufficient to avoid 
deleterious effects from both hyperglycemia and hyperlipidemia. 
Tight glycemic regulation is the primary goal in preventing and managing diabetes clinically.  
Aiming for an HbA1c level of 7% or less is recommended for most patients based on the 
UKPDS (United Kingdom Prospective Diabetes Study) [54].  However, obtaining tight glycemic 
control to further lower HbA1c is a double edge sword due to an increased risk for 
hypoglycemia.  Indeed, one large clinical trial (Action to Control Cardiovascular Risk in 
Diabetes study, ACCORD) was terminated due to frequent hypoglycemia and higher 
hypoglycemia-induced mortality (22%) in the aggressive glycemic control cohort (HbA1c level 
of 6 % or less) [55].  In contrast, aiming at a healthy lifestyle and promoting weight loss is 
effective in preventing T2DM.  Several large intervention studies have demonstrated dietary 
treatment and physical exercise could reduce diabetes risk, lower mortality rate and even 
improve metabolic syndromes in American [56], Swedish [57], Finnish [58], Chinese [59], 
Japanese [60] and Indian [61] racial populations.  For instance, the Diabetes Prevention Program 
(DPP) is one of the largest randomized controlled clinical trials of 3, 234 US adults with 
impaired glucose tolerance [56].  This study included a larger proportion of women (68%) and 
ethnic minorities (45%) and compared lifestyle intervention with drug intervention (metformin 
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850 mg twice daily) over 2.8 years.  Although both interventions showed beneficial effects of 
reducing diabetes risk and improving glucose tolerance, lifestyle intervention also improved 
fasting triglycerides and high-density lipoprotein (HDL)-cholesterol, and decreased the incidence 
of hypertension.  Interestingly, lifestyle intervention demonstrated more effective reduction in 
the risk for developing diabetes than metformin intervention, especially in older people.  
Therefore, a diet of reduced fat intake, increased vegetable consumption with moderate caloric 
restriction and 30-40 min of moderate physical activity on all or most days of the week is 
recommended for effective disease intervention.  
Gestational Diabetes and Other Sub-types 
Gestational diabetes is carbohydrate intolerance resulting in hyperglycemia during 
pregnancy.  It can lead to serious health risks to the mother and infants and increases the risk for 
developing T2DM later in life [1].  The IDF estimates that 21.4 million or 16.8% of live births to 
women in 2013 have hyperglycemia in pregnancy [4].  The Hyperglycemia and Adverse 
Pregnancy Outcome (HAPO) study showed that a pregnant woman’s blood glucose is 
proportional to her risk for developing pregnancy complications [62].  Formal systemic testing 
for gestational diabetes is usually performed between 24 and 48 weeks of gestation.  The 
diagnostic criteria are the same as with other types of diabetes.  The woman should be re-
evaluated as diabetic, IGT, or normal glucose tolerance through an OGTT six weeks or more 
after delivery. 
Other specific sub-types of diabetes are associated with genetic defects of β-cell function and 
are formally referred to as maturity-onset diabetes of the young (MODY).  Common forms of 
MODY are due to mutations in the genes for hepatocyte nuclear transcription factor (HNF) 4-α 
(MODY-1), glucokinase (MODY-2), HNF1-α (MODY-3) and insulin promoter factor-1 
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(MODY-4).  In general, all forms of MODY alter insulin production or glucose metabolism in 
the β-cell.  Other genetic defects that alter insulin action include Leprechaunism and Rabson-
Mendenhall syndrome, endocrinopathies, diseases of the exocrine pancreas and drugs such as 
glucocorticoids that can also induce diabetes. 
1.1.4. The Action of Insulin  
As a central regulator, insulin plays an indispensable role in metabolism of glucose, amino 
acids (AA) and FFAs, which in turn feedback on insulin synthesis and secretion [63].  Insulin 
promotes the synthesis of glycogen, lipid and protein.  Glucose, AA and FFA stimulate insulin 
secretion to maintain a certain circulating concentration of insulin, especially after food intake.  
On the other hand, as glucose levels decrease, glucagon secretion from pancreatic α-cells 
increases to promote glycogenolysis and gluconeogenesis in the liver, in order to avoid 
hypoglycemia.  Therefore, the balance between insulin and glucagon is the key regulator of 
proper metabolic homeostasis.  Deficits of insulin signaling contribute to the development of 
both T1DM and T2DM.  Without proper interventions, diabetes can cause life-threatening 
consequences.  
In healthy subjects, insulin gene expression, insulin synthesis and release are tightly 
regulated to meet metabolic demands.  Insulin is produced in the pancreatic β-cells that are 
clustered in structures called islets.  Pancreatic islets are surrounded by capillaries with high 
permeability to aid in sensing changes in plasma glucose concentration and release the 
corresponding amount of insulin.  Glucose enters β-cells via the GLUT-2 transporter that is 
expressed on β-cells.  GLUT-2 is an insulin-independent glucose transporter with low substrate 
affinity and mediates the facilitated diffusion of glucose into the β-cells.  Glucose is 
phosphorylated to glucose-6-phosphate (G6P) by the rate-limiting enzyme glucokinase, which is 
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also expressed in hepatic cells and glucose-sensitive neurons.  Similar to GLUT-2, glucokinase 
also has a lower glucose affinity compared to other hexokinases.  Due to this low-glucose-
affinity feature, insulin secretion quickly declines as glucose levels fall and this relationship 
helps keep blood glucose above a certain threshold to avoid hypoglycemia. 
Oxidation of G6P via glycolysis and the tricarboxylic acid (TCA) cycle in mitochondria lead 
to the production of ATP.  An increase in the intracellular ATP/ADP ratio closes an ATP-
sensitive potassium (K+ATP) channel on the plasma membrane.  The closure of the K+ATP 
channels depolarizes the plasma membrane and in turn opens the voltage-dependent calcium 
(Ca2+) channel.  Calcium influx triggers granule exocytosis and insulin secretion.  This process is 
called “ATP-sensitive K+ATP channel-dependent insulin release”, which is the basis of GSIS 
(Figure 1.1.4.1) [63]. 
 
Figure 1.1.4.1: Model for coupling of glucose metabolism to insulin secretion in the β-cell.  
Glucose enters into β-cell and is phosphorylated by glucokinase.  Pyruvate produced by 
glycolysis enters the mitochondria and serves as the fuel for mitochondrial respiration, resulting 
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in the generation of ATP and an increased cytosolic ATP/ADP ratio.  Subsequently, the closure 
of K+ATP channels depolarizes the cell membrane, and opens the voltage-dependent Ca2+ 
channels.  Calcium influx into cytosol triggers insulin exocytosis [64]. 
 
Insulin interacts with insulin receptor, which belongs to a large family of growth factor 
receptors with an intrinsic tyrosine kinase activity.  Insulin receptor is a heterotetramer composed 
of two extracellular insulin-binding α subunits and two transmembrane tyrosine kinase β 
subunits.  After insulin binding, insulin receptor undergoes trans-phosphorylation on multiple 
tyrosine residues of the β subunits, leading to the activation of the kinase activity and tyrosine 
phosphorylation of a number of insulin receptor substrate (IRS) proteins [65].  IRS proteins 
function as docking proteins to recruit downstream intracellular proteins.  These protein-protein 
interactions are pivotal in transmitting the signal from the receptor to downstream cellular 
pathways, such as translocation of GLUT4 to plasma membrane, activation of glycogen or 
protein synthesis and the initiation of certain gene transcription. 
1.1.5. Mitochondrial Dysfunction in β-cell Death 
In diabetic individuals, β-cells are either damaged completely with little or no insulin 
secreted in T1DM, or overwhelmed by excessive glucose that can cause impaired insulin release 
and function in T2DM.  Both types of diabetes may eventually result in β-cell apoptosis and loss 
of β-cell mass.  Mitochondrial dysfunction and oxidative stress have been linked to β-cell death 
in both T1DM and T2DM.  Glucotoxicity and/or glucolipotoxicity induce intracellular oxidative 
stress by compromising mitochondrial electron transport chain activity [63].  Reactive oxygen 
species (ROS) such as superoxide anion (O2־·), hydroxyl radicals (OH·) and hydrogen peroxide 
(H2O2) are byproducts from normal mitochondrial electron transport chain function and can 
participate in physiological reactions.  For instance, low levels of H2O2 induce GSIS in isolated 
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mouse islets [66].  However, prolonged oxidative stress increases endogenous antioxidant 
enzymes but inhibits GSIS.  These data suggest that oxidative stress may temporarily provide a 
protective defense but prolonged ROS production can initiate β-cell dysfunction [67].  In this 
regard, animal studies have shown that increased ROS generation is associated with 
mitochondrial dysregulation in diabetes [68]. 
Mitochondrial dysfunction can be reflected by changes in organelle morphology.  
Mitochondria are highly dynamic organelles that maintain a balance between fusion and fission 
to ensure organellar integrity (Figure 1.1.5.1) [69].  Fission is critical to clear out dysfunctional 
mitochondria from the mitochondrial network.  The mitochondrial network divides 
asymmetrically to generate a pool of fragments containing functional mitochondria (shown in 
red), partially defective but reparable mitochondria (shown in yellow), and completely damaged 
units (shown in blue).  Dysfunctional mitochondria are degraded through mitophagy (Step 3), 
whereas reparable units are stabilized and rescued by fusion with fully functional mitochondria 
(Steps 2 and 4).  Pro-fission proteins, including cytosolic dynamin-related protein (DRP) 1 [70] 
and the outer-mitochondrial membrane protein FIS1 [71] play important roles in regulating 
mitochondrial division.  Elongated mitochondria undergo fission through recruiting cytosolic 
DRP1 to FIS1 on the outer mitochondrial membrane.  DRP1 oligomerizes and induces 
constriction of the mitochondrial outer membrane by hydrolyzing GTP [72].  Mitochondrial 
fusion is mediated by optic atrophy 1 (OPA1) and mitofusin (MFN) 1/2 proteins.  The fusion 
process allows exchange of normal mitochondrial DNA copies and membrane components.  
Daughter mitochondria re-integrate into the mitochondrial network (Step 5) for the next cycle. 
Alterations in the mitochondrial fission-fusion process may be involved in certain disease 
conditions, since dysfunction of MFN2 is associated with peripheral neuropathy of Charcot-
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Marie-Tooth (CMT) Type 2A disease [73].  Similarly, mutations in OPA1 contribute to 
autosomal dominant optic atrophy (ADOA) disease [74]. 
 
Figure 1.1.5.1: Schematic model for the role of mitochondrial shaping proteins and 
dynamics of fission-fusion process.  Step 1, mitochondria are elongated to form mitochondrial 
network.  With the help of pro-fission protein DRP1 and FIS1, mitochondrial network divides 
into a pool of fragmented mitochondrial components.  Partial defective but reparable unites 
would fuse with fully functional units (Step 2 and Step 4).  However, completed damaged units 
would go to mitophagosome and be degraded (Step 3).  After exchanging mitochondrial DNA 
copies and membrane components, daughter mitochondria could re-enter the next cycle of 
fusion-fission process (Step 5) [75]. 
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Altered mitochondrial morphology in β-cells has been observed in T2DM animal models [64, 
76] and Type 2 diabetic patients [77].  The islets from Zucker Diabetic Fatty (ZDF) rats, which 
develop obesity and hyperglycemia, contain a larger proportion of short swollen mitochondrial 
fragments (48%) or a combination of long and short fragments (44%), compared to the 
corresponding Zucker Lean Control (ZLC) rats, which only have 5% fragmented mitochondria 
[76].  Similarly in T2DM patients, diabetic islets have a similar number of mitochondria, but a 
disintegrated network and higher mitochondria density volume.  This is associated with lower 
ATP levels, a decrease in the ATP/ADP ratio and an impaired mitochondrial membrane potential 
[77].  Downregulation of the pro-fission proteins DRP1 or FIS1 decreased mitochondrial 
autophagy.  The subsequent accumulation of damaged mitochondrial components including 
oxidative mitochondrial proteins reduces mitochondrial respiration and GSIS [78].  In addition, 
mice with a β-cell specific deficiency in the pro-fusion protein OPA1 developed IGT due to 
impaired proliferation and insulin release.  This was associated with disrupted mitochondrial 
structure (complex IV) and reduced ATP production [79].  Therefore, the balance between 
fission and fusion needs to be tightly regulated to maintain normal mitochondrial function but 
mitochondrial dysfunction might be the cause or the result of aberrant morphology. 
1.2. Diabetic Complications 
Hyperglycemia causes systemic damage not only to islets but also to other organs to induce 
diabetic complications such as cardiovascular disease, nephropathy, retinopathy and neuropathy.  
Large randomized, clinical trials have demonstrated the strong correlation between risks of 
developing diabetic complications and hyperglycemia in both T1DM [80] and T2DM [81, 82].  
The Diabetic Control and Complications Trials (DCCT) compared intensive and conventional 
therapy in 1, 441 T1DM patients with an average 6.5-year follow-up.  Compared to conventional 
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therapy of one or two daily insulin injections, intensive therapy with three or more daily insulin 
injections to further lower HbA1c effectively reduced the incidence and slowed the progression 
of diabetic complications.  Similarly in T2DM, the UKPDS recruited 5, 102 newly diagnosed 
T2DM patients with an average 10 years follow up.  Though intensive insulin therapy resulted in 
a final median HbA1c of 7.0% that was only 0.9% lower than that achieved in the conventional 
therapy group, the incidence of diabetic complications benefited from lowering chronic blood 
glucose levels.  However, other trials with T2DM patients have not seen a clear benefit between 
reducing complications with tight glycemic control.  Nonetheless, these clinical trials provided 
remarkably valuable evidence that tight glycemic control is beneficial to overall metabolic 
improvement and can reduce the risk rate of diabetic complications in both T1DM and possibly 
some people with T2DM.  A caveat is that this benefit comes at an increased risk for recurrent 
hypoglycemia. 
1.2.1. Diabetic Retinopathy 
Diabetic retinopathy is a condition that causes progressive damage to the retina.  As a serious 
sight-threatening microvascular complication of diabetes, diabetic retinopathy is the leading 
cause of visual impairment and even blindness in the working age population and contributes to 
50% of total blindness cases [83].  Though retinopathy occurs rarely in the first 3-5 years after 
the onset of diabetes, nearly all T1DM patients and more than 60% of T2DM patients develop 
retinopathy within two decades of diabetes [84].  In 2010, 92.6 million adults had diabetic 
retinopathy globally [85].  4.2 Million diabetic patients aged 40 years or older have diabetic 
retinopathy in the US and of those, 655, 000 have advanced diabetic retinopathy [5].  
Economically, diabetic retinopathy costs $500 million per year for health care and disease 
treatment in the US [86].  The DCCT found that intensive glycemic control reduced the risk of 
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developing retinopathy by 76% in the primary prevention population, and 54% in the secondary 
prevention population who already had retinopathy.  The UKPDS also showed a 25% reduction 
in the need for retinal laser treatment in T2DM patients with intensive insulin therapy.  However, 
10 years of follow-up in these studies showed that advanced diabetic retinopathy was not 
completely prevented, even in the intensive therapy groups [83].  Another large study, the 
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) in 996 young-onset diabetic 
patients demonstrated that the incidence and severity of diabetic retinopathy is strongly 
associated with the duration of diabetes.  The prevalence of any form of retinopathy was 8% at 3 
years after the onset of diabetes, 25% at 5 years, 60% at 10 years, and 80% at 15 years [87].  
Other risk factors of diabetic retinopathy include hypertension, hypercholesterolemia, genetic 
factors and pregnancy.  Both the WESDR and the UKPDS established the relationship between 
hypertension and worsening of diabetic retinopathy. 
The International Clinical Disease Severity Scale [88, 89], based upon the WESDR and Early 
Treatment of Diabetic Retinopathy Study (ETDRS), divides disease progression into five stages.  
The first is “no apparent retinopathy”.  The second stage is “mild non-proliferative diabetic 
retinopathy” (NPDR), which is characterized by the presence of a few microaneurysms.  The 
third stage is “moderate NPDR” with the presence of microaneurysms, intra-retinal hemorrhages 
or venous beading.  “Severe NPDR”, the fourth stage, is the key level to determine whether laser 
treatment is required.  The final stage is “proliferative diabetic retinopathy” (PDR), which is 
marked by neovascularization, vitreous hemorrhage or traction-induced retinal detachment, 
resulting in vision loss.  Co-existing diabetic macular edema (DME) could also contribute to 
vision loss. 
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Diabetic retinopathy is mostly asymptomatic.  Generally, the symptoms include seeing spots 
floating in the field of vision, blurred vision, having a dark or empty spot in the center of the 
visual field and visual deficits at night.  By the time impaired vision is observed, pathology 
might be significantly advanced.  Thus, there is an urgent need for screening and early diagnosis.  
The American Academy of Ophthalmology has recommended screening for diabetic retinopathy 
5 years after disease onset in T1DM patients, and at the time of diagnosis in T2DM patients.  
Dilated fundus examination should be performed annually if no retinopathy symptom has been 
detected.  If mild NPDR is present, exams should be repeated every 9 months; moderate NPDR, 
every 6 months; severe NPDR, every 3 months.  Patients with proliferative diabetic retinopathy 
should be examined every 2 to 3 months.  Diabetic pregnant women should be examined every 3 
months, since retinopathy can progress rapidly due to hormone changes [90].  For a definite 
diagnosis, fluorescein angiography or optical coherence tomography (OCT) should be performed 
to check the blood vessels and retinal thickness [91, 92]. 
The major pathophysiology of diabetic retinopathy manifests as thickening and swelling of 
the macula, microaneurysm formation and neovascularization.  Various hyperglycemia-linked 
biochemical mechanisms have been shown to directly or indirectly contribute to diabetic 
retinopathy, such as enhanced polyol pathway flux, over activation of the protein kinase C (PKC) 
pathway, advanced glycation end-product (AGEs) formation, chronic inflammation, oxidative 
stress and local hypertension [92].  Additional contributing factors include dysregulated growth 
factors, such as insulin growth factor (IGF) and vascular endothelial growth factor (VEGF) [93, 
94].  Clinical studies have found a higher serum concentration of IGF-I [95] and VEGF [96] in 
diabetic patients, which correlated with higher frequency of PDR or moderate NPDR.  Both IGF-
I and VEGF can stimulate proliferation, increase blood vessel permeability and promote 
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neovascularization.  Serum levels of IGF can be affected by insulin therapy.  Acute increases in 
circulating IGF after insulin therapy is initiated may explain the early worsening of diabetic 
retinopathy.  Antibody-based targeting of VEGF has become a new strategy to treat retinopathy.  
Currently, pegaptanib [97], bevacizumab [98], ranibizumab [99] and VEGF-trap [100] are 
undergoing clinical trials and have showed beneficial effects against diabetic retinopathy and 
DME.  However, blocking IGF-I or VEGF action has been found to cause retinal cell death [92, 
93].  Therefore, long-term safety and therapeutic dosage need to be further investigated. 
Current treatments of diabetic retinopathy or DME consist of mainly two aspects, controlling 
hyperglycemia and its related biochemical pathways, or alleviating disease symptoms.  
Hyperglycemia-linked therapies include insulin to control systemic glucose levels, aldose 
reductase inhibitors (ARIs), PKC inhibitors, angiotensin receptor blocker (ARB), antioxidant, 
and intravitreal injection of anti-VEGF agents and corticosteroids.  Laser photocoagulation is the 
widely used therapy to stop vessel leaking and neovascularization.  The ETDRS found that laser 
photocoagulation effectively reduced the risk of moderate visual loss by 50 % in patients with 
clinically significant macular edema [101].  Early laser photocoagulation treatment could delay 
the disease progression in NPDR and early PDR. 
1.2.2. Diabetic Nephropathy 
Diabetic nephropathy is characterized by persistent albuminuria, higher arterial blood 
pressure and decreased glomerular filtration rate (GFR), which is correlated with a high risk of 
cardiovascular morbidity and mortality [83].  In the US in 2008, 48, 374 new cases of end-stage 
renal disease (ESRD) were attributed to diabetic nephropathy, making it the leading known cause 
of ESRD (accounts for 44%) [5].  Similar to the higher prevalence of diabetic retinopathy in 
T1DM patients, diabetic nephropathy develops in approximately 20% - 40% of T1DM but in less 
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than 20% of T2DM patients.  The peak time of diabetic nephropathy onset in T1DM patients is 
between 10 and 15 years after diagnosis of diabetes. 
The nephron is the functional and structural unit of the kidney and consists of the glomerulus, 
Bowman’s capsule and various collecting tubules.  The glomerulus controls selective substrate 
permeability through its negative charge and pore size.  In the early stages of injury (Stage 1), 
enhanced cellular proliferation of endothelial cells, epithelial cells or mesangial cells results in 
widening of the mesangium [102].  Glomeruli may show only hypertrophy without lesions.  
However, extracellular matrix accumulates within 2 years of diabetes onset (Stage2), progresses 
with increased duration of diabetes, and eventually contributes to glomerular basement 
membrane (GBM) thickening [103].  Lesions comprised of thickened GBM, mesangial 
expansion and the presence of microalbuminuria (Stage 3) are the hallmarks of diabetic 
glomerulopathy.  Diffuse mesangial lesions are progressive.  Aggressive extracellular deposition 
of precipitated plasma protein leads to formation of Kimmelstiel-Wilson nodules, falling GFR 
and the onset of macroalbuminuria (Stage 4), which typically occur 15 years or more after the 
start of diabetes.  All these changes disrupt the structure of the nephron and causes tissue 
ischemia and declined GFR.  Without intervention, patients with macroalbuminuria will develop 
ESRD and kidney transplant therapy will be required [83]. 
Besides hyperglycemia per se, hypertension, ethnicity (African American, Mexican 
American, and Pima Indians), genetic factors, abnormal GFR, increased sodium-lithium and 
sodium-hydrogen counter-transport, and other renal disease could all enhance the risk of diabetic 
nephropathy development.  The ADA recommends annual screening for all T2DM patients and 
for T1DM patients 5 years after onset [104].  Currently available tests for screening and 
diagnosis of diabetic nephropathy include the measurement of albumin-to-creatinine ratio (ACR) 
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in a random spot collection, a 24-h collection to calculate creatinine clearance, and a timed (4-
hour or overnight) urine collection.  A Urinary Albumin Excretion (UAE) rate within 30 to 299 
mg/24 h (equivalent to 20-199 µg/min on a timed sample or 30-299 mg/g creatinine on a random 
spot sample) is considered microalbuminuria.  UAE that is above the upper threshold is 
considered macroalbuminuria.  Acute hyperglycemia, hypertension, urinary tract infections and 
exercise could temporarily elevate UAE.  Therefore, all abnormal tests must be confirmed in two 
out of three samples collected over a 3 to 6-month period, before a definite diagnosis and 
initiation of treatment [105].  Measurement of urinary excretion of N-acetyl-beta-D-
glucosaminidase (NAG) and NAG-to-creatinine ratio are also predictive parameters for early 
diagnosis.  In addition, downregulation of podocyte-specific proteins including synaptopodin, 
podocin and nephrin could be critical pre-clinical markers to detect kidney damage prior to 
microalbuminuria, but are difficult to assess [106]. 
Similar to diabetic retinopathy, intensive glycemic control can help decrease the incidence of 
diabetic nephropathy; it reduced the incidence of microalbuminuria by 39% in the DCCT and 
30% in the UKPDS.  Hypertension is the most common co-morbidity with hyperglycemia.  
Hypertension accelerates the progression of diabetic nephropathy through the renin-angiotensin 
aldosterone system (RAAS), which plays an integral role in regulating arterial pressure, tissue 
perfusion and extracellular volume [107].  Renin and its receptor, (Pro) renin receptor (PRR), 
could enhance the renal production of inflammatory cytokines such as TNF-α and IL-1β [108].  
Angiotensin (Ang) II induces podocyte injury and extracellular matrix accumulation via an 
increase in ROS production, the expression of mesangial transforming growth factor (TGF)-β 
[109] and VEGF synthesis [110]. 
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Monotherapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor 
blockers (ARB) is currently recommended as the first line therapy against microalbuminuria or 
diabetic nephropathy.  Captopril is an ACE inhibitor that considerably decreased the creatinine 
concentration and effectively lowered the risk of death, dialysis, and transplantation by 50% in 
T1DM patients [111].  Losartan is an ARB that significantly reduced the incidence of elevated 
serum creatinine concentration by 25%, and ESRD by 28%, but had no effect on altering 
mortality rate in T2DM patients [112].  More importantly, these protective effects are synergistic 
with the benefit from blood pressure control.  Combined therapy of pharmacological treatments 
and blood pressure control showed greater protection than either hypertension control or drug 
monotherapy alone [112].  Therefore, this combined therapy is frequently used in clinical 
practice for optimal outcomes [113].  As the disease progresses to ESRD, dialysis is needed.  
Generally, patients have better outcomes with transplantation than dialysis.  For T1DM patients, 
a combined kidney-pancreas transplant leads to better outcomes than kidney transplantation 
alone [83]. 
1.2.3. Cardiovascular Disease 
Hyperglycemia and co-existing hypertension, insulin resistance and dyslipidemia induce 
structural damage in the heart, resulting in ventricular dysfunction and ultimately congestive 
heart failure (CHF).  Clinical manifestations include atherosclerosis, diabetic cardiomyopathy, 
coronary artery disease and peripheral vascular disease [114, 115].  Cardiovascular disease is the 
most common cause of death in diabetic patients, accounting for 68% among patients aged 65 
years or older [5].  Postprandial glucose and HbA1c levels are correlated with the risk of 
cardiovascular disease and its associated mortality.  The UKPDS showed a linear correlation, 
such that for every percentage point decrease in HbA1c, there was a 25% reduction in diabetes-
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related deaths and an 18% reduction in myocardial infarction [81].  Similar protective results 
were also detected in the DCCT.  However, as discussed above, with aggressive glycemic 
control aiming at an HbA1c level of 6% or less, the Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) showed no 
beneficial effects [116].  Similarly, the ACCORD study found a 22% higher mortality rate, 
which was persistent after a 5-year follow up.  Therefore, lowering HbA1c level to 8% or less is 
recommended.  In addition, controlling blood pressure has been demonstrated effective in 
lowering the risk of cardiovascular disease in diabetic patients [117].  The ADA recommends 
controlling blood pressure to less than 130/80 mm Hg in diabetic patients [118].  No further 
protection is observed in diabetic patients with systolic blood pressure (SBP) less than 120 mm 
Hg.  Other available treatments include metformin, aspirin and lipid-lowering therapy.  Healthy 
lifestyle including low-fat diet, weight loss and exercise is also highly encouraged to prevent 
cardiovascular disease in diabetic patients. 
1.3. Diabetic Neuropathy 
Diabetic neuropathy is the nervous system disorder caused by chronic hyperglycemia, and 
affects about 60% to 70% of diabetic patients.  Clinical symptoms include impaired sensation or 
pain in the feet or hands, slowed digestion of food in the stomach, carpal tunnel syndrome and 
erectile dysfunction.  Severe forms of diabetic nerve damage are the major causes of non-
traumatic lower-limb amputations, accounting for 60% of total amputation cases [5]. 
1.3.1. Classification and Clinical Features 
There are two main systems to classify diabetic neuropathy that are based on either the 
clinical symptoms or the potential underlying pathophysiology.  Table 1.3.1.1 summarizes the 
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subgroups based on clinical patterns.  On the other hand, diabetic neuropathy can be attributed to 
metabolic-microvascular-hypoxic mechanisms (including DPN and DAN), inflammatory 
immune reactions, the presence of other diabetic complications (such as ketoacidosis, renal 
failure and large vessel ischemia) and treatment-induced nerve damage [119, 120].  It is 
clinically common that diabetic patients develop different forms of diabetic neuropathy 
simultaneously, since pathological mechanisms co-exist under systemic hyperglycemia. 
Table 1.3.1.1: The classification of diabetic neuropathy based on clinical patterns 
 
Diabetic Autonomic Neuropathy (DAN) 
DAN develops in nearly 50% of diabetic patients and affects many organs resulting in 
cardiovascular, gastrointestinal, urinary, sweat gland and genitourinary dysfunction [120, 121].  
DAN may occur as early as one year after the onset of diabetes and progress with the duration 
and severity of DPN [119].  Table 1.3.1.2 summarizes the main clinical manifestations of DAN 
[122].  Unfortunately, due to the diversity of symptoms, DAN usually goes unnoticed.  
Symmetry Type of Neuropathy Subtype
Symmetrical Diabetic polyneuropathy (DPN)
Diabetic autonomic neuropathy (DAN)
Painful distal neuropathy with weight loss, “diabetic 
cachexia”
Insulin neuritis
Hypoglycemic neuropathy
Polyneuropathy after ketoacidosis
Polyneuropathy with glucose impairment
Chronic inflammatory demyelinating polyneuropathy 
(CIDP) in diabetes
Asymmetrical Diabetic radiculoplexus neuropathies Lumbosacral (DLRPN)
Thoracic (DTRN)
Cervical (DCRPN)
Mononeuropathies Median neuropathy at the wrist (MNW)
Ulnar neuropathy at the elbow (UNE)
Peroneal neuropathy at the fibular head
Cranial neuropathies Oculomotor palsy
Abducens palsy
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Orthostatic hypotension is the most easily recognized symptom.  Patients could experience 
fatigue, visual blurring, weakness, and a failure of blood pressure maintenance after standing or 
exercise.  Gastroparesis might worsen the hyperglycemic condition due to retained food in the 
stomach.  Cardiovascular autonomic dysfunction (CAD), including silent ischemia, arrhythmia 
and stroke, are the major life-threatening concerns to cause DAN-associated cardiac death and 
mortality. 
Table 1.3.1.2: Clinical manifestations of Diabetic Autonomic Neuropathy 
 
Diabetic Sensorimotor Polyneuropathy (DPN) 
DPN is the most common form of diabetic neuropathy, characterized by length-dependent 
lower-limb sensorimotor nerve fiber dysfunction, and loss of myelinated and unmyelinated nerve 
fibers.  Sensory nerve injury occurs earlier and progresses more severely than motor nerve 
neuropathy.  DPN is manifested by a variety of “positive” and “negative” sensory symptoms.  
Positive symptoms are often worse at night and consist of hyperalgesia and excessive tingling 
and burning sensations.  This painful diabetic neuropathy usually develops in the early stage of 
diabetes and has been shown to be associated with injury of small unmyelinated fibers [123, 
124].  Most DPN patients also present negative symptoms, such as numbness and loss of 
sensation.  Since diabetic patients with negative symptoms might be unaware of the sensory 
injury, the worst outcome could be foot ulceration and eventual foot/limb amputation. 
Cardiovascular Gastrointestinal Genitourinary Miscellaneous
Orthostasis Oesophageal dysfunction Erectile dysfunction
Hypoglycemia 
unawareness
Exercise intolerance Gastroparesis Retrograde ejaculation Heat intolerance
Arrhythmia Diarrhoea
Reduced vaginal 
lubrication
Argyll Roberson pupil
Silent ischemia Constipation Neurogenic bladder Sweating disturance
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Electrophysiological tests are the gold standard to diagnose the onset of neuropathy and to 
predict disease progression.  The severity of nerve conduction abnormalities correlates with the 
severity of hyperglycemia and underlying changes in nerve fiber structure.  Nerve conduction 
deficits have been detected in diabetic patients, even without signs of neuropathy [125, 126].  
Decreased amplitudes indicate the pronounced axonal degeneration in DPN, whereas the slow 
nerve conduction velocities suggest demyelination [119].  However, diabetic patients may 
present both slow nerve conduction velocity and decreased amplitude when they are diagnosed 
with DPN. 
One limitation of the electrophysiological test is that it provides a more accurate evaluation 
for myelinated motor nerves (predominantly Aα fibers) than sensory nerves, especially small 
unmyelinated C-fibers.  Thus, Quantitative Sensory Testing (QST) is performed to determine 
sensory nerve function.  QST measures a patient’s sensory detection thresholds to heat/cold and 
vibratory stimulation that is mediated mostly by unmyelinated C-fibers and thinly-myelinated Aδ 
fibers, respectively.  However, QST relies on a patient’s psychosensory response and could be 
subject to bias. 
Morphologic studies using teased nerve fibers can accurately evaluate nerve structural 
changes.  Sural nerve biopsy is usually performed due to its relatively distal position and the fact 
that it consists of predominantly thinly-myelinated Aδ fibers and small unmyelinated C-fibers.  
Studies have shown that the nerve fiber diameter distribution shifted to more small unmyelinated 
nerves in DPN patients.  This could be attributed to an increased detachment of Schwann cell 
from axons and a decreased axonal diameter.  However, no significant changes of myelinated 
nerve density and myelin thickness were detected [127-129]. 
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One major problem of nerve biopsy is its invasiveness.  In contrast, with minimal and 
reversible injury, skin biopsy can be used to quantify the small unmyelinated nerve fibers 
innervating the epidermis with a high sensitivity [130-132].  It has been used to diagnose and 
stage the disease status of small fiber neuropathy in patients [133] and animal models [134, 135].  
A 3 mm diameter and 3 mm depth punch biopsy is collected and undergoes immunohisto-
chemistry with antibody against protein-gene-product 9.5 (PGP 9.5), which is an ubiquitin C-
terminal hydroxylase expressed in all nerve fibers.  Intraepidermal nerve fibers density (IENFD) 
is counted to determine unmyelinated nerve innervation [136].  Reduced IENFD has been 
detected in patients suffering from T1DM [137], T2DM [138] and IGT.  A strong negative 
correlation between IENFD and the duration of diabetes has been found in T2DM patients [138, 
139]. 
Therefore, these techniques provide accurate information with the sub-types of the injured 
nerve fibers, the impaired nerve function and the severity of nerve damage (Figure 1.3.1.3).  
Meanwhile, these methods are critical parameters to evaluate the efficacy of clinical therapies. 
Table 1.3.1.3: Nerve Fiber Types in Peripheral Nervous System 
 
Motor
Myelinated Myelinated
Thinly-
myelinated
Un-
myelinated
Thinly-
myelinated
Un-
myelinated
Aα Aα/β Aδ C Aδ C
Touch Cold Warm
Vibration Pain Pain
Position Perception Perception
Peception
IENFD
GIT & GUT function
Autonomic
Heat rate
Blood pressure
Sweating
Sensory
QST
Muscle control
SNCV
MNCV
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1.3.2. Animal Models of Diabetic Peripheral Neuropathy 
Diabetic rodents are widely used experimental models to mimic the neuropathy symptoms 
that are seen in diabetic patients.  They are useful tools to investigate the pathophysiology of 
DPN and evaluate the efficacy of novel therapies.  Streptozotocin (STZ) is the most commonly 
used reagent to induce T1DM in experimental rodents due to its cytotoxic effects on pancreatic 
β-cells [140].  However, the dose of STZ and the rodent background may influence the onset and 
the severity of DPN.  On the other hand, genetically modified rodents can develop obesity and 
hyperglycemia, making them well-characterized models for T2DM. 
Type 1 Diabetic Models 
C57BL/6 is the most common strain of inbred laboratory mice.  It is widely used for disease 
models or gene targeting studies.  A single high dose of STZ injection can induce diabetes as 
well as some neuropathic symptoms in C57BL/6 mice [141, 142].  However, this method is 
problematic due to its toxicity and high post-injection mortality rate.  Instead, several low doses 
of STZ injections are used to improve the survival rate of diabetic animals.  We previously 
demonstrated that STZ i.p. injections at doses of 75, 60, and 45 mg/kg were sufficient to induce 
hyperglycemia and certain neuropathic symptoms, such as mechanical and thermal hypoalgesia 
and the decreased motor nerve conduction velocity (MNCV) without any changes of sensory 
nerve conduction velocity (SNCV), or IENFD after 12 weeks of diabetes [143], whereas the 
mice that injected with a regimen of STZ at doses of 85, 70, and 55 mg/kg developed deficits in 
both decreased MNCV and SNCV after 18 weeks of diabetes [144].  In contrast to the C57BL/6 
mice, diabetic Swiss Webster mice develop severe neuropathy including decreased nerve 
conduction velocities, sensory hypoalgesia and a reduced IENFD, which might be attribute to 
their outbred background [145-147].  One study reported a significant decrease in axonal areas 
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and myelin thickness in both sciatic and sural nerves from diabetic Swiss Webster mice after 5 
months of diabetes [148].  These results suggest that the Swiss Webster mouse is a better model 
in this aspect of neuropathy (Table 1.3.2.1).  The rat is another commonly used laboratory rodent 
model with a longer lifespan compared to mice.  Many groups induced T1DM in Sprague-
Dawley rats with a single low dose of STZ and found sensory hypoalgesia, nerve conduction 
velocity deficits, loss of IENFD and the decreased myelinated fiber areas in diabetic nerves 
compared to age-matched control rats [149-151].  Another study also showed demyelination in 
diabetic Long-Evans suckling rats [152]. 
Table 1.3.2.1: Mouse model comparison C57BL/6 vs. Swiss Webster 
Model 
Duration 
(Weeks) 
STZ 
(mg/kg
/days) 
Sensory 
Testing 
NCV Anatomy Citation
C57BL/6 9 150 NA 
Decreased 
SNCV/MNCV 
NA [141]  
C57BL/6 6 180 
No changes 
in 
mechanical 
sensitivity 
NA 
Decreased 
DRG neuron 
size 
[142]  
C57BL/6 12 
75, 60, 
45 
Mechanical/
Thermal 
Hypoalgesia 
Decreased 
MNCV 
No changes in 
SNCV 
No changes 
in IENFD 
[143]  
C57BL/6 18 
85, 70, 
55 
Mechanical/
Thermal 
Hypoalgesia 
Decreased 
SNCV/MNCV 
NA [144]  
Swiss 
Webster 
24 100/2 
Thermal 
Hypoalgesia 
Decreased 
SNCV/MNCV 
NA 
[145]  
Swiss 
Webster 
26 100/2 
Mechanical/
Thermal 
Hypoalgesia 
Decreased 
SNCV/MNCV 
Decreased 
IENF 
[147] 
Swiss 
Webster 
36 
85, 70, 
55 
 
NA Decreased 
SNCV/MNCV 
Decreased 
IENF, DRG 
neurons loss 
 [146] 
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Swiss 
Webster 
20 
60, 50, 
40 
 
 
NA 
Decreased 
SNCV/MNCV 
Decreased 
axonal areas 
and 
myelination 
thickness 
[148]  
 
Type 2 Diabetic Models 
Spontaneous genetic mouse models, such as the BKS.Cg-m+/+Leprdb/J (BKS-db/db) mouse 
and the B6.Cg-Lepob/J (B6-ob/ob) mouse develop diabetic symptoms similar to Type 2 diabetic 
patients.  The BKS-db/db mice express a mutant in the gene encoding the leptin receptor, 
resulting in deficient leptin receptor activity.  On the other hand, the B6-ob/ob mice express a 
leptin mutant and cannot produce leptin.  Both models develop severe obesity, hyperinsulinemia 
and hyperglycemia beginning at approximately 4 weeks of age.  These mice also develop 
neuropathic symptoms including increased sensory latencies, decreased nerve conduction 
velocities and a reduced IENFD [153, 154].  High-fat diet can induce hyperglycemia and insulin 
resistance in C57BL/6 mice to mimic T2DM.  This mouse model presents peripheral nerve 
dysfunction but no structural abnormalities [155].  Type 2 diabetic rat models include the 
WBN/Kob rat and the Zucker diabetic fatty (ZDF) rat.  Similar to Type 1 diabetic rat models, 
these Type 2 diabetic rats develop distal degeneration [156] and segmental demyelination [157, 
158], nerve dysfunction and sensory impairment in long-term diabetes.  These results suggest 
that diabetic rat models may be more vulnerable to diabetes-induced demyelination. 
1.3.3. Pathology, Current Management and Treatments 
Diabetic rodent models provide useful tools to investigate the pathophysiology in diabetic 
patients and to evaluate the efficacy of clinical therapies.  Several metabolic pathways have been 
shown to be perturbed in diabetic patients and animal models due to systemic hyperglycemia, 
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such as the enhanced formation of AGEs, increased polyol pathway flux, abnormal PKC 
pathway activation, chronic inflammation and mitochondrial dysfunction.  Dysregulation of 
these pathways contribute to the development of various diabetic complications including 
diabetic neuropathy. 
Due to the high prevalence and severity of diabetic complications, great efforts have been put 
forth to identify effective treatments and prevention of diabetic complications.  Currently, tight 
glycemic control remains to be the first line strategy to prevent and/or delay the onset of diabetic 
complications.  Strategies targeting secondary metabolic pathways are also gaining attention and 
a broad range of agents, such as receptor antagonists and enzyme inhibitors, can be potentially 
used to alleviate symptoms of diabetic complications. 
Advanced Glycation End-products Pathway 
Glucose undergoes non-enzymic reaction with amino groups of proteins to form stable 
advanced glycation end-products (AGEs) [159].  The rate of this reaction is directly proportional 
to glucose concentration [160, 161].  Accumulated AGEs directly alter protein function, gene 
expression, and subcellular signal transduction pathways in target tissues.  For instance, AGEs 
have been shown to modify peripheral nerve myelin protein and contribute to segmental 
demyelination [162].  In addition, AGE modified plasma proteins are recruited to AGE receptors 
(RAGE), which stimulate downstream signaling pathways, such as MAPK and NF-κB, and 
induce the production of ROS [163].  In a long-term STZ-induced Type 1 diabetic mouse model, 
RAGE deletion decreased diabetes-induced activation of NF-κB and PKC in peripheral nerves, 
particularly in Schwann cells [148].  These diabetic RAGE-deficient mice showed improved 
nerve conduction velocity and nerve structural parameters, suggesting that blocking AGE 
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formation and RAGE activation could be potential therapeutic strategies against diabetic 
neuropathy. 
Several clinical strategies have been developed to prevent or modulate glycation formation 
and its associated tissue damage.  Aminoguanidine was the first compound designed to inhibit 
AGE synthesis and effectively reversed abnormalities of peripheral nerve function and improved 
peripheral nerve blood flow in diabetic animal models [164].  However, the human clinical trial 
of aminoguanidine (the ACTION II in Type 2 diabetic patients) was terminated due to safety 
concerns, such as gastrointestinal disturbance, liver function abnormalities and an apparent lack 
of efficacy [165].  Another approach to block AGE signaling is to use the AGE cross-link 
breakers, such as ALT-711, to release the covalently bound AGE from proteins.  However, no 
agents are clinically approved to block AGE/RAGE signaling in diabetic patients. 
Polyol Pathway  
The polyol pathway converts glucose to fructose through a two-step reaction: First, aldose 
reductase (AR) reduces glucose to sorbitol with the cofactor nicotinamide adenine dinucleotide 
phosphate (reduced form, NADPH). Sorbitol dehydrogenase (SDH) then oxidizes sorbitol to 
fructose using the cofactor nicotinamide adenine dinucleotide (oxidized form, NAD+) [161, 166]. 
AR has a low affinity for glucose that ensures the activity of polyol pathway is minimal in 
non-diabetics.  However, hyperglycemia shuttles excessive glucose into this pathway, resulting 
in increased consumption of NADPH and accumulation of sorbitol.  This process depletes the 
available NADPH for regenerating antioxidant glutathione (GSH).  Thus, the cells are more 
susceptible to oxidative stress [167].  A strong correlation has been reported between AR gene 
expression and the risk of developing diabetic complications [168, 169].  In addition, the 
elevated fructose production could promote the AGE formation and the activation of PKC 
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pathway [170].  Therefore, the polyol pathway has become a target of drug intervention for 
diabetic neuropathy. 
In a Type 1 diabetic mouse model, AR deficiency reversed diabetes-induced reduction of 
nerve conduction velocity and the accumulation of sorbitol.  Aldose reductase inhibitors (ARI) 
are designed to block the formation of sorbitol and prevent NADPH depletion.  Fidarestat 
effectively reversed nerve conduction velocity defects and small nerve fiber damage in diabetic 
animals [171].  Epalrestat is a clinically approved ARI for use in Japan since 1992.  A 3-year 
clinical trial in Japanese patients found that Epalrestat moderately delayed the progression of 
diabetic neuropathy and ameliorated the associated symptoms [172, 173], suggesting that polyol 
pathway partially contributes to the development of diabetic neuropathy.  However, results with 
ARIs have been generally disappointing in humans and none are approved in the US.  Similarly, 
the efficacy of sorbitol dehydrogenase inhibitors (SDIs) is controversial due to inconsistent 
results across studies [174-176]. 
Protein Kinase C Pathway 
PKC pathway contributes to the pathophysiology of diabetic neuropathy mostly through its 
effects on vascular blood flow.  Activated PKC increases the expression of the angiogenic 
proteins VEGF and TGF-β [177].  These proteins could alter vasoconstriction and capillary 
permeability to cause hypoxia, angiogenesis, basement membrane thickening, and endothelial 
proliferation [178, 179].  The PKC inhibitor Ruboxistaurin completely reversed diabetes-induced 
nerve conduction velocity defects, thermal hyperalgesia and reduced neurovascular blood flow in 
a Type 1 diabetic rat model [179].  Based on these promising results, Ruboxistaurin showed 
significant improvement in neuropathy symptoms with no serious side effects in phase I-II 
human clinical trials [180-182].  Similarly, diabetic retinopathy and diabetic nephropathy also 
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benefited from Ruboxistaurin therapy [181].  Given that microvascular dysfunction is a common 
fundamental contributor to these diabetic complications, regulating blood flow and 
vasoconstriction through inhibiting PKC pathway may be beneficial to different diabetic 
complications.  Indeed, the manufacturer, Eli Lilly Co., is developing Ruboxistaurin for the 
prevention of vision loss in patients with diabetic retinopathy and is waiting for the approval 
notification from the Food and Drug Administration (FDA).  However, Ruboxistaurin for 
diabetic peripheral neuropathy has not been successfully demonstrated in phase III clinical trials, 
whereas further development is needed to determine the effects of Ruboxistaurin on diabetic 
nephropathy [183]. 
Inflammation Pathway 
Hyperglycemia-induced activation of various signaling cascades stimulates NF-κB and the 
activity of iNOS.  Increased production of NO contributes to microvascular damage by 
diminishing the blood supply to nerves, which could lead to tissue ischemia, axon and myelin 
degeneration, and the development of neuropathic pain [184].  iNOS deficiency preserved 
normal nerve conduction velocities and prevented the loss of IENFD in a STZ-induced Type 1 
diabetic mouse model [185].  The NF-κB-mediated extensive infiltration of macrophages and the 
release of cytokines from endothelial cells exacerbated cellular oxidative stress and nerve 
damage [186]. 
Cyclooxygenase (COX) is the rate-limiting enzyme in prostaglandin (PG) synthesis, which is 
involved in inflammatory response.  The expression of COX-2 (the inducible form of COX) was 
upregulated in peripheral nerves and dorsal root ganglia (DRG) neurons in diabetic animal 
models [187].  A selective COX-2 inhibitor and COX-2 gene inactivation prevented the diabetes-
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induced peripheral nerve dysfunction, oxidative stress and inflammation [187].  These results 
indicate that COX-2 could be a potential therapeutic target in DPN. 
Oxidative Stress and Mitochondrial Dysfunction 
Mitochondrial oxidative phosphorylation is the major pathway for ATP synthesis.  In this 
process, electrons from reducing substrates, such as nicotinamide adenine dinucleotide (reduced 
form, NADH) and flavin adenine dinucleotide (reduced form, FADH2), are transferred to 
molecular oxygen, producing H2O.  Through respiratory chain complexes I-IV embedded on the 
inner mitochondrial membrane, a proton gradient across the inner mitochondrial membrane is 
established, driving ATP synthesis by ATP synthase. 
Though the electron transport system is precisely organized and regulated, 1-4% of the 
oxygen is incompletely reduced, forming ROS such as superoxide anion.  Low levels of ROS are 
reduced by antioxidant enzymes, such as superoxide dismutase (SOD), catalase, and glutathione 
peroxidase (GP).  However, hyperglycemic cells metabolize excessive glucose through 
glycolysis, the TCA cycle and oxidative phosphorylation, producing an over-abundance of ROS.  
In addition, hyperglycemia-driven over activation of cellular signaling pathways (discussed 
above) could further contribute to ROS generation.  Accumulated ROS can impair mitochondrial 
function by damaging mitochondrial DNA, proteins and membrane integrity, and also by 
disrupting the fusion-fission process that controls mitochondrial morphology and mitochondrial 
number [188]. 
As a major antioxidant, Mn-SOD or SOD-2 (mitochondrial form of SOD) is critical for 
cellular development and survival, since deletion of the SOD-2 gene is prenatally lethal [189].  
Decreased expression of Mn-SOD has been found in the db/db Type 2 diabetic mouse model and 
is associated with worse neuropathy symptoms [190].  In addition, our lab previously 
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demonstrated that hyperglycemic treatment induced oxidative stress and decreased Mn-SOD 
expression in primary DRG neuron cultures [191].  Overexpression of Mn-SOD prevented the 
formation of mitochondrial ROS in vitro [190], suggesting that Mn-SOD is a critical regulator 
against oxidative stress in mitochondria.  Therefore, antioxidant agents have become a potential 
strategy to increase the reducing potential against cellular oxidative stress. 
α-Lipoic acid (ALA) is a natural cofactor in enzymatic reactions, which could directly 
terminate free radicals, chelate transition metal ions, and increase cytosolic GSH levels [192].  
One promising phase III clinical trial, the SYDNEY trial, demonstrated that intravenous 
administration of ALA significantly reversed positive neuropathy symptoms and improved nerve 
function in Type 2 diabetic patients [193].  Similarly, oral administration of ALA also 
demonstrated protective effects on diabetic patients in the SYDNEY 2 trial [194].  Though ALA 
treatment benefited patients by both administration routs, the limitation of these clinical trials is 
the short duration in the investigation (3-5 weeks).  To this end, the Neurological Assessment of 
Thioctic Acid in Neuropathy (NATHAN) 1 trial was a 4 year study of oral treatment with 600 
mg/d of ALA in 460 diabetic patients with mild to moderate DPN [195].  ALA did not improve 
nerve conduction but modestly improved some scores of small fiber neuropathy.  Part of this lack 
of efficacy in the NATHAN 1 trial was due to the lack of worsening of nerve conduction deficits 
in the placebo-treated group [195]. 
In summary, multiple metabolic pathways interact and induce oxidative stress in diabetes.  
Currently, other than intensive insulin intervention, no pharmacologic therapy could prevent or 
delay the onset and progression of diabetes-induced complications.  Moderate improvement from 
targeting a specific pathway indicates that multiple mechanisms are involved in the disease 
development, and novel targets need to be investigated. 
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1.4. Growth Factors in Peripheral Nervous System 
Growth factors are critical regulators in the nervous system both during the development and 
after nerve injury.  In the peripheral nervous system (PNS), certain neural crest cells migrate 
from the neural plates form melanocytes in the skin, or generate Schwann cell precursors (SCPs).  
SCPs then differentiate to immature Schwann cells, which can develop into myelinating and non-
myelinating Schwann cells that ensheath large and small diameter axons, respectively.  
Myelination is selectively activated in myelinating Schwann cells that envelop single large 
diameter axons.  The development and myelination of nerve fibers is a dynamic and tightly 
regulated process, which is dependent on survival factors, mitogens and differentiation signals 
from axons.  Meanwhile, Schwann cells provide essential trophic support for sensory and motor 
neurons.  Another important feature of this process is plasticity.  Mature myelinating and non-
myelinating Schwann cells can revert to immature Schwann cell by dedifferentiation in response 
to nerve injury and re-entering the cell cycle (Figure 1.4.1) [196].  Given the essential function 
of growth factors in the developing PNS and the plasticity of the Schwann cell lineage, impaired 
expression levels of growth factors may render neurons and Schwann cells more vulnerable to 
hyperglycemic stress. 
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Figure 1.4.1: Schematic illustration of the main cell types and developmental transitions 
involved in Schwann cell development.  Dashed arrows indicate the reversibility of the 
transition from mature myelinating and non-myelinating cells to immature Schwann cell.  The 
embryonic phase of Schwann cell development involves three transition processes: the migration 
of neural crest cells, the differentiation of SCPs into immature Schwann cells, and the maturation 
into myelinating and non-myelinating Schwann cells.  Schwann cells enveloping single large 
diameter axons differentiate into mature myelinating cells, whereas Schwann cells that ensheath 
small diameter axons become mature non-myelinating cells [196]. 
 
1.4.1. Neurotrophin Family 
Neurotrophins play specific roles in the development, maintenance and regeneration of sub-
populations of peripheral nerve fibers [197, 198].  The neurotrophin family includes nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 
and NT-6.  They are initially synthesized as proneurotrophins, which are subsequently cleaved 
and released as mature proteins.  Neurotrophins fulfill their functions through activating their 
receptors including high affinity tropomyosin-related kinase (Trk) receptors and low affinity p75 
neurotrophin receptors (p75NTR) [199].  NGF activates Trk A receptor and/or p75NTR on small 
sensory and autonomic nerve fibers.  NT-3 stimulates Trk C signaling on large nerve fibers, 
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whereas BDNF and NT-4/5 may exert their effects on medium-sized fibers through the Trk B 
receptor [200]. 
Nerve Growth Factor 
NGF was discovered in the 1950s and is the first member of the neurotrophin family. It is 
synthesized in a variety of cell types, including muscle cells, keratinocytes, sympathetic neurons, 
DRG neurons and Schwann cells [200, 201].  Blocking NGF-Trk A signaling is devastating to 
the development of nervous system, since both NGF [202] and Trk A receptor [203]. 
In STZ-induced Type 1 diabetic rodent models, NGF levels are decreased in sympathetic 
neuron-innervated target organs, such as muscle, skin [204], sensory neurons and sciatic nerves 
[205].  Allogeneic pancreatic islet transplantation that restored euglycemia reversed the 
decreased NGF levels and improved nerve function [206].  Similarly, reduced NGF levels were 
detected in the submandibular gland in the db/db Type 2 diabetic mouse model [207], suggesting 
that the synthesis of NGF might be disturbed by hyperglycemia. 
As a target-derived neurotrophin, NGF activates Trk A receptor and forms a “signaling 
endosome” in distal nerve terminals.  The endosome complex is retrogradely transported up long 
axons to the proximal cell bodies in order to promote neuronal survival [208].  Retrograde axonal 
transport of NGF is decreased in diabetic rats [209].  Decreased synthesis in distal axonal termini 
and reduced retrograde transport induce a lack of NGF-mediated support for neuronal survival.  
Therefore, these results triggered a number of studies to investigate the efficacy of treating 
diabetic rodents with exogenous NGF as a replacement therapy.  Intrathecal or subcutaneous 
administration of recombinant human NGF (rhNGF) reversed multiple indices of diabetic 
neuropathy, including impaired C-fiber function [210], mechanical [211] and thermal 
hypoalgesia [212], declined myelin thickness [213] and the loss of IENFD [211]. 
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In contrast, little is known about the NGF profile in diabetic patients.  DPN patients have low 
serum NGF levels, which correlated with decreased motor nerve conduction velocity [214].  One 
group detected increased expression of p75NTR along the whole degenerating fibers in DPN 
patients, suggesting a potential compensating mechanism of nerve tissue repair [215].  However, 
studies from human skin biopsies showed controversial results.  An increase in NGF mRNA 
[216] and Trk A mRNA levels [217], but a decrease in protein levels of NGF and its precursor 
[218, 219] were found in skin biopsies from DPN patients.  These inconsistent results indicate 
that translational/post-translational modifications may affect the NGF profile in diabetic patients. 
Given the protective effects of rhNGF in diabetic animal models, a phase I-II human clinical 
trial was conducted in 250 patients who were sub-grouped to receive placebo, 0.1 µg/kg rhNGF 
or 0.3 µg/kg rhNGF subcutaneously [220].  Though injection site hyperalgesia was reported, 6-
month rhNGF treatments significantly improved the neurological examination parameters and 
QST scores.  However, disappointing outcomes were found in a 12-month phase III trial in 505 
patients [221].  In this trial, a dose of 0.1 µg/kg was chosen to avoid injection site pain, which 
was still severe compared to the placebo treatment.  Other than a moderate improvement of the 
global symptom assessment, no significant therapeutic benefits were demonstrated.  Several 
potential reasons may have caused the failure in the phase III trial.  For instance, 0.1 µg/kg of 
dose could be at the edge of its effective threshold.  With a different manufacturing method in 
the phase III trial, the bioactive concentration could be below the efficacy window.  More 
importantly, NGF affects mainly small sensory nerves and autonomic nerves consisting of 
thinly-myelinated Aδ fibers and unmyelinated C-fibers.  Nerve conduction studies and QST 
performed in clinical trials may not reflect any improvement in this specific sub-population of 
nerve fibers affected by the NGF treatment.  Therefore, structural and functional tests of C-fiber 
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integrity, such as IENFD and measures of skin blood flow, might overcome the end point 
limitations.  On the other hand, these negative results could be attributed to the inefficient drug 
delivery system.  Cytomegalovirus (CMV) immediate-early promoter and herpes simplex latency 
active promoter 2 were used to deliver NGF into the DRG, adipose tissue and the footpad of 
diabetic mice.  In these NGF-treated diabetic mice, decreased sensory nerve amplitude was 
prevented [222].  In summary, NGF is indeed a potential therapeutic agent against diabetic 
neuropathy.  However, further human studies and a modified drug delivery system are needed. 
Brain-derived Neurotrophic Factor and Neurotrophin-3 
BDNF and NT-3 are detected in a variety of cell types, such as sensory neurons, sympathetic 
neurons, motor neurons and their targeted organs (skin and muscle) [223].  STZ-induced Type 1 
diabetic rats showed an increase in BDNF mRNA levels in muscle, DRG and sciatic nerve [224, 
225], but a transient decrease in Trk B receptor mRNA levels in sciatic nerve [226].  The 
retrograde accumulation of BDNF was decreased in diabetic rats, but not due to impaired 
receptor-mediated uptake [227].  The inconsistency between increased BDNF mRNA levels but 
decreased protein accumulation suggests that translational/post-translational modifications could 
play an essential role to regulate the function and expression of neurotrophins.  Exogenous 
BDNF treatment of diabetic rats protected against MNCV deficits and myelin damage in motor 
nerve fibers.  However, no improvement has been observed on sensory nerve-related function 
[228]. This suggests that BDNF may have more effects on myelinated motor nerves than small 
unmyelinated fibers, which may explain the negative results in human clinical trials using sural 
nerve conduction and cutaneous axon-reflexes as end point parameters [229]. 
The third member of neurotrophin family is NT-3, which was also decreased in sciatic nerve, 
hindlimb skeletal muscle and DRG neurons in STZ-induced Type 1 diabetic rats [230].  These 
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diabetic rats also showed reduced axonal transport of NT-3 in sciatic nerves.  Exogenous NT-3 
delivery by adenovirus-based gene therapy prevented the motor and sensory nerve conduction 
velocity deficits in diabetic rats [231].  In contrast, skin biopsies from diabetic patients showed 
increased NT-3 protein expression levels [232] and Trk C mRNA levels [217].  Unlike the 
promising efficacy in diabetic animal models, a phase I trial of recombinant-methionyl human 
NT-3 (r-metHuNT3) was discontinued due to no significant improvement in neurologic function, 
though the dosage was tolerated and the most reported side effect was mild injection site pain 
[233]. 
1.4.2. Insulin-like Growth Factor Family 
Due to the sequence homology to proinsulin, the Insulin-like Growth Factor (IGF) family is 
well-studied.  The IGF family consists of IGF-I and IGF-II and mediate their function by 
activating the IGF receptor (IGFR).  IGF-I is broadly expressed throughout the nervous system 
such as brain, spinal cord, sensory DRG neurons, and sciatic nerves, whereas IGF-II is more 
enriched in the brain and motor neurons.  IGF signaling is critical to normal development and the 
maintenance of the nervous system since deleting the IGFR is embryonic lethal [93]. 
STZ-induced Type 1 diabetic rats showed reduced serum levels of IGF-I compared to control 
rats [234].  mRNA levels of both IGF-I and IGF II were also decreased in sciatic nerves from 
these diabetic rats [235].  Subcutaneous infusion of either IGF-I or IGF-II effectively reversed 
the hyperalgesia in this Type 1 diabetic rat model [236].  Similarly, in ZDF Type 2 diabetic rats, 
IGF-II mRNA levels were decreased in brains, spinal cord, sciatic nerves and liver, whereas 
IGF-I mRNA levels were only reduced in liver [237].  Thus, IGF-II, but not IGF-I, was injected 
subcutaneously to diabetic rats and restored the normal sensory thresholds. 
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Though few studies have been conducted to investigate the changes of IGFs in diabetic 
patients, one group detected decreased serum levels of IGF-I and IGFR in Type 2 diabetic 
patients with neuropathy.  Interestingly, a clinical trial in Type 1 diabetic patients demonstrated a 
transient but significant reduction of HbA1c levels with daily subcutaneous injections of 40 
μg/kg recombinant human IGF-I (rhIGF-I) [238].  These results suggest that IGF could serve as a 
supplementary therapy to conventional insulin therapy.  However, whether IGFs could protect 
against diabetic neuropathy needs further study. 
In summary, many diabetic animal studies and human clinical trials have been conducted to 
investigate the efficacy of growth factors as replacement therapies against diabetic neuropathy.  
Unfortunately, no agent has been approved clinically to treat diabetic neuropathy.  Injection site 
pain is widely reported, suggesting that high exogenous amounts of growth factor at the injection 
sites could be harmful to the surrounding skin tissues.  However, the concentration that actually 
reaches nerve tissues might be below the effective threshold.  Tissue-targeted delivery may 
specifically restore the growth factor concentration in nerve fibers.  Meanwhile, end point 
parameters of clinical trials might affect the outcome results.  Different assessments should be 
performed to distinguish the response from various nerve fibers. 
However, the major problems with the “growth factor replacement” hypothesis are the 
inconsistency across animal studies and little understanding in diabetic patients.  For instance, 
controversial results have been reported between different laboratories, and/or between protein 
concentrations and mRNA levels within the same group [216, 218, 219].  Thus, multiple factors, 
such as translational/post-translational modifications, diabetic models, duration of diabetes, and 
the tissue types need to be taken into account when interpreting data.  Since no deficiency of NT-
3 has been detected in diabetic patients, the failure of the NT-3 clinical trial is less surprising 
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[233].  This human clinical trial raised a question of whether exogenous injection of any growth 
factor, regardless of the type, would benefit diabetic patients.  More importantly, interactions 
among different types of growth factors play critical stage- and spatial-dependent roles during 
nervous system development.  For instance, BDNF signaling promotes the release of soluble 
Neuregulin-1 (NRG1) from axons to Schwann cells, which is critical to initiate the 
differentiation of SCPs into immature Schwann cells.  Otherwise, SCPs would undergo 
programmed cell death [239].  The interactions between various growth factors maintain a 
balanced network and compensate for dysfunction of one growth factor.  The exogenous increase 
of one growth factor may disrupt the balance and lead to a rather destructive result.  Therefore, 
more understanding of different types of growth factors under diabetic conditions could provide 
broader and more comprehensive insights into the growth factor replacement therapy. 
1.5. Neuregulin-Erb B Signaling in Peripheral Nervous System 
Axonal neuregulins (NRGs) that activate Erb B receptors, which localize primarily to 
Schwann cells, are the key molecules regulating different stages of Schwann cell development 
and myelination.  They also contribute to Schwann cell dedifferentiation and degeneration after 
nerve injury.  However, little is known about how diabetes may affect gliotrophic signaling by 
altering NRG-Erb B signaling in PNS. 
1.5.1. Ligand Neuregulin-1 Family and Erb B Receptors 
The NRG family has four members: NRG1, NRG2, NRG3, and NRG4.  Other than NRG1, 
little is known about the biological functions of NRG2, NRG3, and NRG4 proteins.  The NRG1 
gene is about 1.4 megabases, however, less than 0.3% of this span encodes for protein.  Through 
multiple promoter usage and extensive alternative RNA splicing, more than 30 different isoforms 
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are generated from the single NRG1 gene.  NRG1 isoforms are divided into sub-types based on 
structural features: the type of epidermal growth factor (EGF)-like domain (α or β), the N-
terminal sequence (Type I-VI), and whether the isoform is synthesized as a membrane-associated 
or secreted protein.  All NRG1 isoforms contain the EGF-like domain, which is necessary and 
sufficient to activate Erb B receptors.  NRG1 isoforms with a β-type EGF-like domain are 10 to 
100 times more potent than isoforms with an α-type EGF-like domain.  On the basis of N-
terminal sequence, NRG1 Type I (also known as heregulin, neu differentiation factor, or 
acetylcholine receptor-inducing activity (ARIA)) and NRG1 Type II (also known as glial growth 
factor (GGF)) have N-terminal immunoglobulin (Ig)-like domains.  NRG1 Type III (also known 
as sensory and motor neuron derived factor (SMDF)) is defined by its cysteine-rich domain 
(CRD), which functions as a second transmembrane domain.  Membrane-associated NRG1 
isoforms undergo proteolytic cleavage by metalloproteinases (MP), including α-secretase tumor-
necrosis factor-α-converting enzyme (TACE) and β-secretase β-site amyloid precursor protein 
cleaving enzyme (BACE).  As a consequence, NRG1 Type I and NRG1 Type II are released 
from the cell surface and function as paracrine signaling molecules.  In contrast, due to the 
hydrophobic domain that contains CRD, NRG1 Type III remains tethered to the cell surface after 
cleavage and functions as a juxtacrine signal.  Cytoplasmic domains of NRG1 can be further 
cleaved by γ-secretase and translocate to nucleus (Figure 1.5.1.1).  Sub-types IV-VI with shorter 
N-terminal domains have not been well-characterized.  Within the nervous system, NRG1 Type I 
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and NRG1 Type III are the most abundant isoforms that are detected in many neurons, such as 
spinal motor neurons and DRG neurons, and also in glia [240, 241].  
 
Figure 1.5.1.1: Schematic illustration of different proteolytic cleavages of NRG1 isoforms.  
(a): NRG1 Type I and NRG1 Type II are synthesized as single transmembrane proteins, whereas 
NRG1 Type III has two transmembrane domains.  (b): After metalloproteinase (MP) cleavage, 
NRG1 Type I and NRG1 Type II are released from axonal membrane and act as paracrine 
molecules.  However, NRG1 Type III remains tethered to the membrane due to its cysteine-rich 
domain (CRD) and functions as a juxtacrine signal [240]. 
 
NRG1 isoforms mediate their effects by interacting with Erb B receptors (Erb B2, Erb B3 
and Erb B4 receptor), which are members of the EGF receptor superfamily.  NRG1 binds to Erb 
B receptors and induce conformational changes that trigger dimerization of Erb B receptors.  The 
formation of receptor dimers activates their intrinsic tyrosine kinase activity, which leads to 
cross-phosphorylation on the receptors, recruitment of adaptor molecules and activation of 
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downstream signaling pathways, such as phosphatidylinositol-3-kinase (PI3K) and MAPK 
pathways.  Erb B receptor dimerization is mediated by a unique dimerization arm, which is 
exposed only after a conformational rearrangement promoted by ligand binding.  Though Erb B2 
is a ligand-less receptor, it constitutively exposes a dimerization loop required for dimerization.  
However, due to the lack of shape and/or electrostatic self-complementarity interface, the ability 
to form Erb B2-Erb B2 or Erb B3-Erb B3 homodimers is poor [242].  In addition, Erb B3 
receptor lacks an active kinase domain and Erb B4 receptor is minimally expressed by Schwann 
cells.  The heterodimer Erb B2-Erb B3 is the relevant NRG1 receptor pair in peripheral nerves 
[240]. 
1.5.2. Neuregulin-Erb B Signaling in Peripheral Nerve Development 
Genetic animal models with targeted mutations in the NRG1 gene are valuable tools to 
elucidate the functions of NRG1-Erb B signaling.  Unexpectedly, homozygous pan-NRG1-/- mice 
and Ig-NRG1-/- mice that have both NRG1 Type I and NRG1 Type II sub-types inactivated died 
during embryogenesis (E10.5) due to cardiac malformations [243, 244].  CRD-NRG1-/- mice with 
mutated NRG1 Type III isoforms died at birth (P0) since lung alveoli fail to expand [245].  The 
number of cranial sensory neurons and sympathetic neurons are considerably decreased in all 
three genetic models.  However, only Ig-NRG1-/- mice have normal SCP development [244, 
246].  Though these results demonstrate the importance of NRG1 proteins in embryogenesis, 
early death of these homozygous mice fails to reveal in vivo functions of NRG1 proteins in 
nervous system development and myelination. 
In contrast, heterozygous mice and mice that conditionally express targeted mutations in 
NRG1 can survive to adulthood.  These transgenic mice are useful tools to investigate the role of 
NRG1-Erb B signaling in developing peripheral nerves.  Heterozygous NRG1+/- mice showed 
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hypomyelinated sciatic nerves, which have not been observed in heterozygous Erb B2+/- mice 
[247].  However, transgenic mice that have an inducible complete ablation of Erb B2 perinatally 
in peripheral nerves survived, but lost motor axons and displayed abnormally thin myelin sheaths 
due to a decreased number of myelin wraps [248].  These results indicate that NRG1 might be 
the rate-limiting factor in NRG1-Erb B signaling, whereas Erb B receptors are expressed at 
saturating level.  In addition, the blockade of Erb B receptor activity could lead to aberrant 
development of both myelinated and unmyelinated nerve fibers.  Postnatally, overexpression of 
dominant-negative Erb B4 receptors (DN-Erb B4) under the control of myelinating Schwann cell 
specific 2’, 3’-cyclic nucleotide 3’-phosphodiesterase (CNPase) promoter specifically disrupted 
NRG1-Erb B signaling in myelinating Schwann cells.  These transgenic mice developed 
hypomyelination, shorter internode length and associated mechanical hyperalgesia [249].  Under 
control of the non-myelinating Schwann cell specific promoter for glial fibrillary acidic protein 
(GFAP), overexpression of DN-Erb B4 disturbed the NRG1-Erb B signaling in non-myelinating 
Schwann cells, which resulted in abnormal structure of Remak bundles, loss of unmyelinated 
fibers, extensive Schwann cell death and associated thermal insensitivity [250]. 
Due to the large diversity in the NRG1 family, a series of carefully designed studies 
differentiated the functions between NRG1 isoforms.  All three types are critical to the survival 
and differentiation of SCPs [251, 252] (Figure 1.5.2.1).  NRG1 Type I is the first NRG1 isoform 
expressed in many cell linages at E6.5, followed by NRG1 Type II and a strong expression of 
NRG1 Type III at E10 [246].  Axon-derived NRG1 Type I/II translocated from axon to Schwann 
cell surfaces in the embryonic chick during a critical period of Schwann cell survival. Indeed, 
downregulation of NRG1 Type I/II resulted in an inhibition of SCP differentiation and an 
increase in programmed cell death [239].  On the other hand, NRG1 Type III isoform has major 
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effects on later stage in the development of motor and sensory neurons, including migration 
[253] and myelination [254].  Heterozygous NRG1 Type III+/- mice have thinner myelin sheaths, 
and mice that overexpress NRG1 Type III, but not NRG1 Type I, develop hypermyelination 
[247].  Indeed, only axonal NRG1 Type III rescued the hypomyelination seen in primary 
DRG/Schwann cell co-cultures prepared from heterozygous NRG1 Type III+/- and homozygous 
NRG1 Type III-/- mice [255]. 
 
Figure 1.5.2.1: A stage-dependent model for NRG1 signaling in developing peripheral 
nerves.  From E5 to E7 in chick embryos, SCP survival is dependent on soluble HBD-NRG1 
(NRG1 Type I and NRG1 Type II) that can be increased by local BDNF signaling.  Those SCPs 
that do not receive sufficient levels of NRG1 undergo apoptosis.  Those that survive require 
additional NRG1 signaling to differentiate into immature Schwann cells.  Later, the myelination 
of axons at E14 depends on the concentration of axonal CRD-NRG1 (NRG1 Type III).  HBD, 
heparin-binding domain; BDNF, brain-derived neurotrophic factor; CRD, cysteine-rick domain.  
The red spheres represent the heparin-binding domain, and the blue spheres are the EGF-like 
domain of NRG1 Type I/II [239]. 
 
Activation of the PI3K pathway has been shown to be crucial for Schwann cell survival [256] 
and the initiation of myelination [257].  However, the overall effects of NRG1 isoforms 
primarily depend on the balance between MAPK and PI3K activation [257].  In myelinated 
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DRG/Schwann cell co-cultures, a high-concentration of NRG1 isoforms, regardless of the sub-
type, induced subsequent Schwann cell dedifferentiation [258] and demyelination [259, 260] that 
was linked to activation of ERK pathway [260].  In addition, the JNK pathway could negatively 
regulate myelination through the demyelinating transcription factor c-jun [261, 262].  However, 
the role of p38 pathway in myelination is controversial, since one group found that p38 pathway 
induced demyelination [263], whereas other studies demonstrated that p38 activation is required 
for Schwann cell differentiation and myelination through the pro-myelinating transcription factor 
Krox-20 [264, 265].  Other signaling pathways, such as NF-κB and phosphatase, 
calcineurin/NFAT and tensin homolog (PTEN), are also involved in regulating myelination.  
NRG activates calcineurin and its downstream NFAT and regulates myelination through Krox-
20 [266].  PTEN is a negative regulator of the PI3K pathway and is activated by NRG1 signaling 
to prevent over-myelination [267]. Additionally, NF-κB may serve as a convergent pathway 
downstream of PI3K and ERK activation stimulated specifically by NRG1 Type III to promote 
myelination [268].  Thus, Schwann cell differentiation and myelination is a dynamic process 
regulated by the balance between various NRG1 isoforms and different downstream pathways. 
Since all membrane-associated NRG1 isoforms need to undergo proteolytic cleavage in order 
to be released as bioactive molecules, different secretases could affect the sequence and the 
function of NRG1 isoforms.  BACE1 performs the most important proteolytic cleavage in the 
stalk region of NRG1 Type III and produces the active N-terminal fragment [269].  Deficiency of 
BACE1 resulted in the accumulation of uncleaved NRG1 Type III proteins and hypomyelination 
of peripheral nerves [270].  Interestingly, neuronal overexpression of full-length NRG1 Type III 
still successfully induced hypermyelination in BACE1 null mutant mice, indicating that other 
secretases are also involved in the cleavage and secretion of NRG1 isoforms [271].  α-Secretases 
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include  disintegrin and metalloproteinase (ADAM)10 and ADAM17 (also known as TACE).  
Though ADAM10 has minor effects on NRG1 Type III-mediated myelination [272, 273], TACE 
inhibits myelination in peripheral nerves.  This inhibitory effect might be due to its cleavage site 
within the EGF-like domain of NRG1 Type III, which inactivates the function of NRG1 Type III 
and the downstream PI3K pathway [274].  In contrast, γ-secretases may not be directly related to 
myelination.  The C-terminal domains cleaved by γ-secretases translocate to nucleus and 
represses apoptosis [275], indicating a pro-survival role in neurons. 
1.5.3. Neuregulin-Erb B Signaling in Nerve Injury 
In contrast to the critical role of NRG1 signaling in the development of peripheral nerves, 
NRG1-Erb B signaling is dispensable for maintenance of myelinated peripheral nerves [276, 
277].  However, nerve injury induced a rapid change of NRG1-Erb B signaling.  An acute and 
transient increase in the activity of Erb B2-Erb B3 has been found in the distal stump of damaged 
nerves within the first hour after axotomy [278].  The increased activities of Erb B2-Erb B3 
receptors are associated with Schwann cell demyelination during Wallerian degeneration [279], 
which is the process to remove the transected axons and myelin debris.  In addition, 
Mycobacterium leprae that binds to and activates Erb B2 receptors without dimerization strongly 
activates the ERK pathway and promotes subsequent demyelination [280].  A pharmacological 
inhibitor of the Erb B2 receptor, PKI-166, abrogated axotomy-induced [278] and Mycobacterium 
leprae-induced demyelination [280].  Furthermore, our lab previously demonstrated that over-
activation of Erb B2-Erb B3 receptors in Schwann cells is sufficient to induce peripheral 
neuropathy since the Erb B2 receptor inhibitors, erlotinib and PKI-166, reversed the nerve 
conduction velocity deficits and sensory hypoalgesia [143].  In contrast, one group using 
transgenic mice that overexpress Erb B2 receptors observed improved nerve regeneration after 
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median nerve crush [281], which might be attributed to different nerve injury (nerve crush vs. 
surgical transection). 
Consistent with the increase in Erb B receptor activity after sciatic nerve transection, NRG1 
Type II was increased in the distal nerve stump [282].  More importantly, sural nerve biopsies 
from patients with axonal neuropathy showed an increase in NRG1 Type I in the early stage of 
axonal degeneration [283].  However, NRG1 Type III was dramatically downregulated in 
axotomized motoneurons [284].  A neuropathic pain model (L5 spinal nerve ligation) showed 
increased mRNA levels of NRG1 Type I and Type II, but a decrease in NRG1 Type III mRNA 
levels [285].  Though NRG1 Type II has been found increased after nerve transection, exogenous 
NRG1 Type II may promote nerve repair.  One study demonstrated that NRG1 Type II treated 
rats have less severe degeneration and earlier robust remyelination after sciatic nerve crush, 
which was associated with improved motor nerve function and nerve morphology [286].  Similar 
results with NRG1 Type II treatment have also been observed in a facial nerve axotomy model.  
Interestingly, the beneficial effects of NRG1 Type II treatment are even greater than NGF 
treatment [287].  It remains unclear whether the change of NRG1 isoforms is the primary cause 
to induce Schwann cell degeneration and demyelination, or it is the result from self-regulatory 
response secondary to nerve injury. 
1.5.4. Adapter Protein Erb B2-Interacting Protein 
Erb B2-interacting protein (erbin) is an adapter protein that belongs to leucine-rich repeat 
(LRR) and PDS-95/Discslarge/ZO-1 (PDZ) domain (LAP) family.  The LAP family shares a 
common structural feature of 16 LRRs at the N-terminus and one to four PDZ domains at the C-
terminus.  LAP proteins serve as scaffolding molecules and regulate signal transduction and 
protein-protein interactions in polarized cells such as epithelial cells and neurons. 
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The N-terminal LRRs of erbin can bind to Ras and block its interaction with Raf-1, thereby 
abolishing Ras activation of Raf-1 and inhibiting ERK activation [288, 289].  Erbin may also 
regulate other signaling pathways such as the PI3K [290] and NF-κB pathways [291].  X-ray 
crystallographic studies reveal that erbin contains one PDZ domain, which recognizes the 
peptide sequence EYLGLDVPV corresponding to the C-terminal residues 1247-1255 of Erb B2 
receptor [292, 293].  This interaction is specific to Erb B2, but not Erb B3 or Erb B4 receptor.  In 
addition, erbin is a necessary component of NRG1-Erb B2 signaling pathway.  Erbin could 
reduce NRG1-stimulated Erb B2 receptor endocytosis through binding to non-phosphorylated 
Erb B2 and stabilizing it on the plasma membrane.  More importantly, the sciatic nerves of erbin 
null mice are hypomyelinated [290] and have a decreased number of myelinated fibers after 
nerve injury [294].  These data suggest that erbin has a critical role in both Schwann cell 
myelination and regeneration. 
1.6. Dissertation Hypothesis 
Although it has been established that NRG1-Erb B signaling plays an important role in the 
development of peripheral nerves and regeneration after nerve injury, the changes and function 
of this pathway in diabetic neuropathy remain unclear.  Our lab previously demonstrated that a 
transient increase in Erb B2-Erb B3 receptor activity contributed to the development of diabetic 
neuropathy [143].  Therefore, the aim of the current study is to determine how diabetes affects 
positive and negative regulators Erb B2-Erb B3 receptors.  The NRG1 family is the primary 
ligand for Erb B2-Erb B3 receptors in the PNS and function as positive regulators.  However, 
different sub-types of NRG1 family have distinguished functions.  In contrast, the adapter 
protein erbin negatively regulates Erb B2 activation of the MAPK pathway.  Therefore, the 
overall hypothesis of the current study is that differential expression of NRG1 isoforms and 
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downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral 
neuropathy.  The specific aims for the current study are: 
1. To determine whether changes of NRG1 isoforms and erbin expression are associated 
with Erb B2 receptor activation in DPN. 
2. To determine whether the activation of MAPK pathway is involved in DPN. 
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Chapter 2: Materials and Methods 
2.1. Materials 
2.1.1. Animals 
Wild-type C57BL/6 and Swiss Webster mice were obtained from Harlan Laboratories 
(Indianapolis, IN).  All animals were housed at the Animal Care Unit at the University of Kansas 
on a 12-h light/dark cycle at 70°F and 70% humidity with ad libitum access to water and Purina 
diet 5001 chow.  All animal procedures (e.g. handling, drug administration, euthanasia, tissue 
collection and breeding colony management) were conducted in accordance with protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) and regulations set by 
the National Institutes of Health (NIH). 
2.1.2. Antibodies 
Table 2.1.2.1: List of Primary and Secondary antibodies Utilized in the studies 
Antibody Provider 
Catalog 
No. 
β-actin MP Biomedicals, Solon, OH 691002 
NRG1 Type I Abcam, Cambridge, MA ab27303 
NRG1 Type III (SMDF c-16) Santa Cruz Biotechnology, Santa Cruz, CA sc-33271 
ErbB2 clone 24B5 Millipore Corporation, Billerica, MA 04-291 
Erbin Abcam, Cambridge, MA ab55930 
Phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
Cell Signaling, Boston, MA 9101 
p44/42 MAPK (Erk1/2) Cell Signaling, Boston, MA 9102 
P0 Chemicon, Temecula, CA AB9352 
PGP 9.5 AbD Serotec, Oxford, UK 7863-0504 
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A NRG1 Type III polyclonal antibody was produced in rabbits by Chi Scientific (Maynard, 
MA) using the CIAGLKWVFVDKIFEYDSPTHL peptide sequence near the N-terminal CRD of 
NRG1 Type III as the immunizing antigen. 
2.1.3. Peptide Competition Assay 
Sciatic nerves from untreated wild-type adult mice were homogenized in mRIPA (modified 
Radio Immuno Precipitation Assay) lysis buffer (50 mmol/L Tris–HCl, pH 7.5, 1 mmol/L 
EDTA, 1% Nonidet P-40, 0.5% deoxycholate, 1 mmol/L Na3VO4, 150 mmol/L NaCl, 0.5 
mmol/L sodium molybdate, 40 mmol/L NaF, 10 mmol/L β-glycerophosphate, and 1x Complete 
Protease inhibitors (Roche Diagnostics)), protein lysates were separated by SDS-PAGE and 
transferred onto nitrocellulose.  The various NRG1 antibodies were pre-incubated to buffer or the 
immunizing peptide at a 1:50, 1:100 or 1:200 mass ratio for 1 hour at 25°C prior to their use for 
detecting NRG1 isoforms in the sciatic nerve lysates by immunoblot analysis. 
Immunoblot of sciatic nerve extracts with the custom NRG1 Type III antibody detected a 
prominent band at about 75 kDa (Figure 2.1.3.1), which represents the N-terminal fragment after 
cleavage and is consistent with the protein size previously reported [295].  As a complementary 
approach, we also used a commercial NRG1 Type III antibody that was raised against a region 
within the C-terminal domain of NRG1 Type III (SMDF) and detects a single band at about 65 
kDa.  The immunizing peptide specifically decreased the detection of the 75 kDa NRG1 Type III 
band.  However, the peptide had no effect on detecting NRG1 Type I or the 65 kDa C-terminal 
NRG1 Type III fragment by SMDF c-16 antibody, indicating the 75 kDa band represents the N-
terminal fragment of NRG1 Type III containing the distinct CRD. 
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Figure 2.1.3.1: Validation of specificity of the custom NRG1 Type III antibody.  (A): 
Comparison of NRG1 Type III detection using the custom N-terminal NRG1 Type III polyclonal 
antibody (left) and a commercial C-terminal NRG1 Type III polyclonal antibody (SMDF, right).  
(B-D) Demonstration of the specificity of the N-terminal NRG1 Type III polyclonal antibody.  
The immunizing peptide was preabsorbed in a 1:50 to 1:200 ratio with the indicated amounts of 
the N-terminal NRG1 Type III antibody (B), a polyclonal antibody against NRG1 Type I (C) or 
the C-terminal NRG1 Type III antibody (SMDF, D) for 1 hour at 25°C and then used for 
immunoblot analysis of a sciatic nerve sample.  
 
2.1.4. Reagents 
Streptozotocin (STZ) was obtained from Sigma-Aldrich (St. Louis, MO).  
N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine (erlotinib) was provided 
by OSI Pharmaceuticals (Melville, NY). 
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2.2. Methods 
2.2.1. Induction of Diabetes and Measurement of Fasting Blood Glucose (FBG) 
Eight-week old C57BL/6 and Swiss Webster mice were rendered diabetic through a series of 
intraperitoneal (i.p.) injections of freshly dissolved STZ in 200 μL of sterile sodium 
citrate/sodium chloride solution (10 mmol/L sodium citrate, 154 mmol/L NaCl, pH 4.5).  
C57BL/6 mice were fasted overnight prior to receiving i.p. injections of STZ at doses of 85, 70, 
and 55 mg/kg over three days.  Swiss Webster were fasted 6 hrs prior to receiving i.p. injections 
of STZ at 100 mg/kg for two consecutive days.  Mice were fasted an additional two hrs before 
re-feeding but had ad libitum access to water.  One week after the last injection, mice were fasted 
for 6 hrs and blood was obtained from the tail vein.  FBG was measured with a One-Touch Ultra 
glucometer (Lifescan, Milpitas, CA).  Animals with a FBG concentration ≥ 290 mg/dl (16 
mmol/L) were deemed diabetic.  Mice with FBG < 250 mg/dl were re-administered up to two 
additional STZ injections at 85 mg/kg.  In addition, FBG was measured the day before 
euthanasia to confirm their diabetic status. 
2.2.2. Measurement of Glycated Hemoglobin 
Percent glycated hemoglobin levels were measured using the A1C NOW+ multi test A1C kit 
(Bayer Healthcare, Sunnyvale, CA) immediately before euthanizing the animals.  HbA1C levels 
≥6.5% were consistent with a prolonged diabetic state. 
2.2.3. Assessments of Sensory Sensitivity 
Thermal Sensitivity 
Sensitivity to thermal stimulation was assessed using the Hargreaves Analgesiometer (Ugo 
Basile, Comerio, Italy).  The Hargreaves apparatus was calibrated using a heat flux radiometer.  
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Mice were placed on the glass surface of the apparatus and allowed to acclimate for 30 minutes 
before tests.  Activation of the heat source produced a focal, radiant heat that increased in 
intensity at a rate of approximately 0.3°C/s, which predominantly activates small unmyelinated 
C-fibers and thinly-myelinated Aδ fibers [296].  The heat source was stimulated under the 
plantar surface of alternating hind paws with approximately 5 minutes intervals to avoid 
hyperalgesia.  The length of time required to induce paw withdrawal (in seconds) from three to 
five trials per animal were recorded and averaged. 
Mechanical Sensitivity 
Sensitivity to mechanical stimulation mediated by myelinated Aδ fibers was evaluated using 
the Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio, Italy).  A 0.5 mm diameter steel 
monofilament attached to a force actuator controlled the amount of force produced.  The force 
actuator was calibrated using a 50 g weight.  Mice were placed on the wire mesh platform of the 
apparatus and allowed to acclimate for 30 minutes before testing.  The monofilament was 
activated under the plantar surface of alternate hind paws at an upward force of up to 8 g for 
C57BL/6 mice or 10 g for Swiss Webster mice at a ramping speed of 2 seconds with about 5 
minutes intervals between tests.  The amount of force that induced paw withdrawal (in grams) 
from three to five trials per mouse were recorded and averaged. 
2.2.4. Nerve Conduction Velocity 
Mice were anesthetized with an i.p. injection of 100 mg/kg ketamine and 10 mg/kg xylazine 
in sterile normal saline solution.  Anesthesia was confirmed by evaluating the eye blink reflex 
before initiating the tests.  Body temperature was monitored with a rectal probe connected to 
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Physitemp TCAT-2DF Controller (Physitemp Instruments, Clifton, NJ) and maintained at 37°C 
using a heat lamp. 
Motor and sensory nerve conduction velocities were measured using a TECA™ Synergy N2 
(Carefusion, San Diego, CA) system with 12 mm subdermal disposable platinum/iridium bipolar 
needle electrodes (Cardinal Health Neurocare, Madison, WI). 
Motor Nerve Conduction Velocity 
The sciatic nerve was stimulated proximally at the sciatic notch and distally at the ankle via 
bipolar electrodes with a supramaximal stimulus (9.9 mA) of 0.05 ms duration square wave 
pulse.  The resulting waveforms were filtered with low and high settings of 3 and 10 kHz.  
Latencies were defined as the time between stimulus artifact (Figure 2.2.4.1, position 1) and the 
onset of negative M-wave deflection (position 2).  MNCV (m/s) was calculated by dividing the 
difference between proximal and distal latencies by the distance between stimulating and 
recording electrodes. 
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Figure 2.2.4.1: Representative trace of motor nerve conduction.  A supramaximal stimulus 
(9.9 mA) were induced proximally at the sciatic notch and distally at the ankle.  Latencies were 
defined as the time between stimulus artifact (position 1) and the onset of negative M-wave 
deflection (position 2).   
 
Sensory Nerve Conduction Velocity 
For hindlimb sensory nerve conduction velocity (SNCV), the digital nerve to the second toe 
was stimulated with a square-wave pulse of 0.05 ms duration using the smallest intensity current 
that resulted in a maximal amplitude response, typically 2.4 mA.  The resulting wavelengths 
were filtered with low and high settings of 3 and 10 kHz, respectively.  Ten sensory nerve action 
potentials were recorded behind the medial malleolus and averaged to generate a single 
waveform.  Latency was determined by the time from stimulus artifact (Figure 2.2.4.2, position 
1) to the onset of peak negative deflection (position 2).  The maximal SNCV was calculated by 
dividing the latency by the distance between stimulating and recording electrodes. 
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Figure 2.2.4.2: Representative trace of sensory nerve conduction.  The digital nerve to the 
second toe was stimulated with a square-wave pulse and sensory nerve action potentials were 
recorded behind the medial malleolus.  Latency was determined by the time from stimulus 
artifact (position 1) to the onset of peak negative deflection (position 2). 
 
2.2.5. Erlotinib Administration 
Erlotinib was dissolved in 0.1 M Captisol (CyDex Pharmaceuticals, Lenexa, KS) and 
administered via an i.p. injection at the indicated dose either weekly or twice per week. 
2.2.6. Immunohistochemistry of Footpad Tissue 
The integument of the plantar surface of both hind paws was dissected and fixed in 
Zamboni’s fixative overnight.  Tissues were then rinsed in PBS with sodium azide at 4°C, 
cryoprotected in 30% sucrose overnight, embedded in OCT (Sakura USA, Torrence, CA), frozen 
on dry ice, and stored at -80°C.  Frozen tissues were sectioned at 30 μm, placed on Fisherbrand 
Superfrost Plus microscope slides and stored at -80°C.  Immunohistochemistry was performed 
using the Vectastain Elite ABC-Peroxidase kit for rabbit IgG (Vector Laboratories, Burlingame, 
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CA) and an anti-PGP 9.5 antibody (AbD Serotec, Oxford, UK).  In detail, tissue samples were 
surrounded using a PAP pen (Newcomer Supply, Middleton, WI), incubated in blocking buffer 
containing 10% normal goat serum for 30 minutes followed by incubation in a 1:1000 dilution of 
anti-PGP 9.5 antibody or blocking buffer (negative control) for 3 hours at room temperature.  
Samples were then incubated with secondary antibody for 1 hour at room temperature and 
subsequently treated with an avidin-biotin solution (ABC solution) for 1 hour at room 
temperature.  After incubation with NovaRED peroxidase (Vector Laboratories, Burlingame, 
CA) for 2-3 minutes, the sections were counterstained with hematoxylin for 45 seconds and a 
coverslip applied.  Two slides from each animal were stained and a minimum of twelve images 
per animal were captured using a Zeiss light microscope (Carl Zeiss microimaging, Thornwood, 
NY) with a color CCD digital camera (Diagnostic for Instruments Inc. Sterling Heights, MI) for 
quantification.  Single nerve fibers crossing the dermal/epidermal junction were counted from 
each image.  The IENF density was calculated by the number of fibers counted divided by the 
length of the dermal/epidermal junction (number of fibers/mm). 
2.2.7. Immunoblot Analysis 
Tissues were collected immediately upon euthanasia.  Sciatic, tibial, and sural nerves were 
dissected from both hind limbs and placed in 0.1 to 0.2 ml of mRIPA buffer on ice.  The tissue 
was homogenized with a Polytron fitted with a micro-tissue tearor and the lysate centrifuged at 
10, 000 × g at 4°C for 10 minutes.  The supernatant was collected and stored at -20°C.  Protein 
concentration was determined using the Bio-Rad protein assay.  Ten µg of protein was separated 
by SDS-PAGE and transferred to nitrocellulose.  Membranes were incubated with 5% non-fat 
dry milk in PBS-T (PBS buffer with 1% Tween) for 1 hour at room temperature with gentle 
rocking and probed with primary antibodies at 4ºC overnight.  For detection of phosphorylated 
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protein, 3% bovine serum albumin was used to avoid non-specific blocking of the 
phosphoepitope.  After primary antibody incubation, membranes were washed and further 
incubated with HRP-conjugated secondary antibodies for 2 hours at room temperature.  β-actin 
was probed as a loading control.  Immunoreactivity for each protein was visualized using HRP-
conjugated chemiluminescence detection (GE Healthcare Life Sciences, Little Chalfont, 
Buckinghamshire, U.K.) and exposed to autoradiography film.  Immunoblots were quantified by 
densitometry with the aid of ImageJ (NIH) software and the level of the proteins of interest was 
normalized to β-actin unless otherwise stated.  Changes in protein expression are expressed as a 
percent of the control values. 
2.2.8. Erbin-shRNA Lentivirus Preparation and Infection 
The nucleotide sequence of erbin shRNA was 5’-UAG ACU GAC CCA GCU GGA AdTdT-
3’ [288].  The pENTR™/U6 entry constructs containing erbin shRNA or lacZ-shRNA were 
generous gifts from Dr. Lin Mei, Georgia Health Science University.  Lentiviral vectors were 
generated using BLOCK-iT™ Lentiviral RNAi Expression System according to the 
manufacturer’s manual (Invitrogen, Carlsbad, CA).  Ligation reactions were performed between 
pENTR™/U6 and pLenti6/ BLOCK-iT™-DEST vectors to generate an expression clone 
containing the shRNA sequence.  293FT cells were co-transfected by pLenti6/ BLOCK-iT™-
DEST expression contrast and ViraPower™ Packing Mix to produce a lentiviral stock.  The 
lentiviral stock was stored in -80°C.  To examine the effect of erbin on myelination, the cells 
were infected with lenti-virus expressing erbin-shRNA or control lacZ-shRNA for 16 hours.  
Myelin protein expression levels were assessed by immunoblot analysis 48 hours after infection. 
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2.2.9. Preparation of Myelinated Mouse DRG/Schwann Cell Co-cultures 
DRG neurons were isolated from C57BL/6 pups born at day 0 (P0) into L15 medium as 
previously described [297].  Following dissociation of tissues using 0.25% trypsin and 0.25% 
collagenase at 37ºC for 30 minutes, cells were collected by centrifugation for 5 minutes at 1, 000 
× g and resuspended in DMEM containing 25 mM glucose and 10% fetal calf serum (Atlas 
Biologicals, Fort Collins, CO, U.S.A.).  Cells were triturated, counted with a hemocytometer and 
6-7×104 cells were seeded onto collagen-coated glass coverslips.  The cultures were maintained 
in DMEM maintenance medium containing 100 U/mL penicillin, 100 μg/mL streptomycin 
(Thermoscientific, Logan, UT, U.S.A.), 50 μM gentamycin (MP Biologicals, Solon, OH, U.S.A.) 
and 50 ng/mL nerve growth factor (Harlan Biosciences, Indianapolis, IN, U.S.A.).  Fast-growing 
fibroblasts were removed by treating the cells with 10 μM cytosine β-D-arabinoside for 2 days 
and cultures were maintained in regular medium for one week to allow Schwann cell to 
proliferate and associate with axons.  Myelination was then initiated by addition of 50 μg/ml 
ascorbic acid for 18-21 days in culture with the medium replenished every 2-3 days. 
2.2.10. Preparation of Schwann Cell Cultures 
Sciatic nerves were dissected from postnatal day 2 or day 3 Sprague-Dawley rat pups as 
previously described [298, 299].  The nerves were rinsed with Leibovitz’s L15 medium (L15) 
and incubated with 0.25% collagenase in L15 medium for 30 minutes at 37 °C.  The cells were 
collected by centrifugation for 10 minutes at 1, 000 × g and resuspended in L15 medium 
containing 0.25% trypsin plus 0.25% collagenase for an additional 30 minutes, and protease 
activity was inactivated with DMEM containing 10% fetal calf serum (FCS).  The cells were 
triturated through a fire-polished glass pipette and plated onto poly-D-lysine-coated plates in low 
glucose (5.5 mmol/L) DMEM containing 10% FCS and 2 µM forskolin (complete medium).  
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The cells were grown in the presence of 10 µM cytosine arabinoside for 3 days to remove the 
faster growing fibroblasts and passaged upon confluency after approximately 1 week in culture.  
The Schwann cells were subcultured upon confluency and used for no more than 5 passages.  To 
examine the effects of hyperglycemia and NRGs on Schwann cell mitochondrial function, 
cultures were treated with low glucose or high glucose (25 mmol/L) DMEM medium for 6 days 
and sub-groups were treated with 10 ng/ml NRG1 Type I (recombinant human NRG-1-β1 
epidermal growth factor domain, aa 176-246, R&D Systems, Minneapolis, MN) or 10 ng/ml 
NRG1 Type III (recombinant human NRG1 SMDF isoform, R&D Systems, Minneapolis, MN) 
for 24 hours.  Mitochondrial bioenergetics were measured by Seahorse Biosciences XF96 
Extracellular Flux Analyzer. 
2.2.11. Measurement of Mitochondrial Respiration 
Oxygen consumption rate (OCR) was assessed in intact mouse lumbar DRG sensory neurons 
or primary rat Schwann cells using an XF96 Extracellular Flux Analyzer (Seahorse Biosciences, 
North Billerica, MA).  The maintenance medium was changed to unbuffered Dulbecco’s 
modified Eagle’s medium supplemented with 1 mmol/L pyruvate and 5.5 mmol/L D-glucose 1 
hr prior to the assay and the cells were incubated at 37°C.  The plate was introduced into the 
XF96 analyzer, a 3-minute mix cycle used to oxygenate the medium, and respiration was 
assessed in a 4-minute measurement cycle.  As a general description of a mitochondrial stress 
assay, the initial rates provide a measure of the basal OCR prior to assessing mitochondrial 
dysfunction using respiratory chain poisons.  The portion of basal OCR that is coupled to ATP 
synthesis was estimated by the decrease in OCR following addition of the ATP synthase 
inhibitor, oligomycin (1 µg/ml).  The residual OCR that persists after oligomycin treatment is 
from uncoupled respiration (proton leak).  Next, maximal respiratory capacity (MRC) was 
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assessed following dissipation of the proton gradient across the inner mitochondrial membrane 
with the protonophore FCCP (1µM).  Non-mitochondrial respiration was then assessed by 
coinjection of 1 µM each of rotenone and antimycin A.  After the respiratory measures, the cells 
were harvested and OCR values were normalized to the total protein content of each well.  ATP-
linked respiration, proton leak, maximal respiratory capacity, spare respiratory capacity, and 
respiratory control ratio were determined as described previously [150, 300]. 
2.2.12. Mitochondrial Fraction 
Schwann cells were washed with ice-cold PBS and resuspended in 0.5 ml of cell 
homogenization medium containing 150 mmol/L magnesium chloride, 10 mmol/L potassium 
chloride, 10 mmol/L Tris-HCl, pH 7.4, 0.25 mol/L sucrose and 1x Complete® protease 
inhibitors.  The lysates were centrifuged at 800 × g for 10 minutes at 4°C to get rid of the nuclear 
fraction.  The supernatant was recovered and centrifugation at 8, 000 × g for 10 minutes at 4°C.  
The supernatant was collected as the cytosolic fraction.  The pellet was washed twice with ice-
cold sucrose/Mg2+ medium (150 mmol/L magnesium chloride, 0.25 mol/L sucrose, 10 mmol/L 
Tris-HCl, pH 7.4 and 1x Complete® protease inhibitors) and resuspended in mitochondrial 
suspension buffer (0.25 mol/L sucrose, 10 mmol/L Tris-Base and 1x Complete® protease 
inhibitors).  Immunoblot analysis was performed to detect the Erb B2 levels in the mitochondrial 
fraction. 
2.2.13. Statistical Analysis 
Data are presented as arithmetic means ± SEM.  After verifying equality of variance, 
differences between treatments were determined using a one-way or two-way ANOVA by 
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SigmaStat 3.5.  Differences between group means were ascertained using Tukey’s Honestly-
Significant-Difference post hoc test. 
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Chapter 3: Dysfunction of Neuregulin-Erb B2 Ligand-Receptor 
Signaling Pathway in Diabetic Peripheral Neuropathy 
3.1. Mouse Models of Diabetic Peripheral Neuropathy 
We have previously demonstrated that a transient increase in Erb B2 receptor activation 
contributed to diabetes-induced sensory neuropathy since inhibiting Erb B2 signaling reversed 
some of the pathophysiologic features of DPN [143].  Therefore, disrupted Erb B2 signaling 
might contribute to the axonal degeneration and Schwann cell demyelination in diabetic nerves.  
However, it remains unknown whether the increase in Erb B2 activity in diabetic nerves is 
associated with changes in NRG1 isoforms and erbin that may serve as positive and negative 
regulators of Erb B2 signaling, respectively. 
Experimental mice provide a useful model to investigate the pathophysiology of diabetes and 
its complications.  Since T1DM is the focus in the current study, we used STZ to induce T1DM 
in mice.  However, the dose of STZ injection and the mouse background may influence the onset 
and the severity of DPN.  Consistent with other groups using C57BL/6 mice, we did not observe 
a significant decrease in SNCV and loss of fiber innervation [143].  In contrast, other studies 
have reported that outbred Swiss Webster mice develop severe diabetic neuropathy and are a 
more robust model that better tolerate long-term untreated diabetes [146].  Therefore, we 
compared inbred C57BL/6 and outbred Swiss Webster mice to determine if the later would be 
useful for our study. 
Eight-week old wild type C57BL/6 mice were rendered diabetic with STZ i.p. injections 
daily at doses of 85, 70, and 55 mg/kg, which have been determined to be effective to induce 
diabetes in C57BL/6 mice [144].  Eight-week old Swiss Webster mice were induced diabetic 
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with STZ i.p. injections at 100 mg/kg for two consecutive days.  Mechanical and thermal 
sensitivity were measured as the parameters to compare the severity of neuropathy between 
mouse models. 
In both models, diabetes induced significant mechanical and thermal hypoalgesia as early as 
two weeks after the onset of hyperglycemia, compared to corresponding non-diabetic controls 
(Figure 3.1.1 A and B).  In addition, diabetic Swiss Webster mice required 5% - 15% more force 
to induce paw withdrawal than diabetic C57BL/6 mice did (Figure 3.1.1 C), whereas thermal 
latencies were comparable between two models.  These result suggest that diabetic Swiss 
Webster mice could develop more robust diabetic neuropathy, especially in myelinated nerve 
fibers that mainly contribute to the mechanical sensation. 
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Figure 3.1.1: Mechanical and thermal hypoalgesia in C57BL/6 and Swiss Webster mice 
over 9 weeks of diabetes.  Diabetes induced significant mechanical (A) and thermal (B) 
hypoalgesia in both C57BL/6 and Swiss Webster mice compared to corresponding time-matched 
non-diabetic control mice.  (C): The ratio of withdrawal threshold in diabetic mice compared to 
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control ones within each mouse model.  Diabetic Swiss Webster mice demonstrated more severe 
mechanical insensitivity (blue squires) than diabetic C57BL/6 mice, whereas thermal 
withdrawal latencies (red circles) were comparable between mouse models (*, p < 0.05 for STZ 
vs. time-matched Veh; ^, p < 0.05 for STZ-Swiss Webster vs. time-matched STZ-C57BL/6). 
 
In order to determine the effects of longer-term hyperglycemia on myelin proteins in Swiss 
Webster mice, sciatic nerves were collected from 26-week diabetic mice and time-matched 
control mice.  Protein lysates were separated by SDS-PAGE and probed with an antibody against 
myelin protein zero (P0).  Immunoblot analysis (Figure 3.1.2) showed a remarkable reduction in 
P0 levels in diabetic sciatic nerves, which was not been observed in our previous study in 
C57BL/6 mice [143].  Although morphological studies such as g-ratio measurement and teased 
nerve fibers are needed to determine demyelination, a decrease in compact myelin protein P0 
levels suggest that diabetes might induce worse nerve damage and sensory deficits in Swiss 
Webster mice, especially in myelinated nerve fibers, through compromising the myelin sheath 
components. 
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Figure 3.1.2: Decreased P0 expression levels in sciatic nerves of Swiss Webster mice after 
26-week diabetes.  Diabetic Swiss Webster mice (STZ) demonstrated a significant reduction of 
P0 expression levels in sciatic nerves after 26-week diabetes compared to non-diabetic control 
mice (Veh).  Levels of P0 are normalized to β-actin levels (**, p < 0.01 for STZ vs. Veh). 
 
3.2. Dysfunction of NRG1-Erb B2 Signaling in Diabetic Swiss Webster Mice 
To elucidate the role of altered NRG1-Erb B2 signaling in DPN, we used diabetic Swiss 
Webster mice, which after prolonged diabetes develop severe pathophysiologic symptoms of 
DPN [146].  Figure 3.2.1 shows the time-course of the current study.  Swiss Webster mice were 
rendered diabetic with STZ injections and after 12 weeks of diabetes, treated with erlotinib once 
a week for 4 weeks and twice a week for an additional 4 weeks.  Sensory tests (Von Frey and 
Hargreaves) and nerve conduction velocity studies (MNCV and SNCV) were conducted to 
measure sensory thresholds and nerve function.  IENFD was performed to detect changes in 
small fiber innervation.  Peripheral nerve samples (sciatic, tibial and sural nerves) were collected 
at weeks 9, 12, 16 and week 21 and immunoblot analysis was performed to detect changes in 
NRG1 isoforms and erbin expression. 
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Inhibition of Erb B2 signaling partially reversed several pathophysiologic aspects of DPN 
including a pronounced sensory hypoalgesia, nerve conduction velocity deficits and the decrease 
in epidermal nerve fiber innervation (Chapter 3.3)  In addition, we observed that diabetes 
altered the expression of NRG1 Type III and NRG1 Type I in distal nerve fibers with increasing 
duration of diabetes.  In particular, a decrease in NRG1 Type III expression was accompanied by 
an increased expression of NRG1 Type I level in diabetic sural nerves and tibial nerves 
(Chapter 3.4).  Furthermore, the expression of erbin was decreased in sciatic nerves of diabetic 
mice and this corresponded with an increase in p42/p44 MAPK pathway activity (Chapter 3.5).  
These data are the first to characterize that diabetes can alter the expression of proteins that serve 
as positive and negative regulators of Erb B2 activity and suggest that an altered neuregulinism 
may contribute to Schwann cell pathology in DPN [301]. 
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Figure 3.2.1: Time-course of the current study.  Swiss Webster mice were rendered diabetic 
with STZ injections, at the time that considered week 0.  FBG measurements at week 1 were 
performed to confirm the status of hyperglycemia.  After 12 weeks of diabetes, mice were sub-
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grouped and received 25 mg/kg erlotinib or vehicle once a week for 4 weeks and twice a week 
for additional 4 weeks.  Starting at week 2, behavior tests (Von Frey and Hargreaves) were 
initiated.  Nerve conduction velocity studies (MNCV and SNCV) and IENFD study were 
performed between (at week 12) and after (at week 21) the erlotinib treatments.  Peripheral nerve 
samples were collected at week 9, 12, 16 and week 21. 
 
3.3. Erb B2 Receptor Inhibitor Attenuates Pathophysiological Indices of Diabetic 
Peripheral Neuropathy 
Swiss Webster mice were rendered diabetic with STZ and changes in mechanical and 
thermal sensitivity were monitored for 12 weeks to assess the onset of hypoalgesia in both 
myelinated (mechanical) and unmyelinated (thermal) nerve fibers.  Diabetic mice showed a 
significant increase in both paw withdrawal force and thermal latency, indicating mechanical 
(Figure 3.3.1 A) and thermal (Figure 3.3.1 B) hypoalgesia.  To address whether Erb B2 
signaling contributed to the sensory deficits, mice were treated at week 13 with vehicle or 25 
mg/kg erlotinib, which is a clinically approved inhibitor of the EGFR that can also inhibit Erb B2 
receptors [143].  The mice were initially given one treatment per week for 4 weeks and this 
modestly improved mechanical and thermal sensitivity.  Increasing the frequency of dosing to 
twice per week (Figure 3.3.1 A and B, dashed arrows) yielded a greater improvement in 
mechanical sensitivity, but thermal sensitivity did not change beyond that seen with a single dose 
per week. 
In order to directly assess the nerve function, we measured the motor (MNCV) and sensory 
(SNCV) nerve conduction velocity.  Consistent with the sensory hypoalgesia, both MNCV and 
SNCV were significantly decreased after 12 weeks of diabetes compared to non-diabetic animals 
(Figure 3.3.2 A and B).  After 8-weeks of erlotinib treatment, the pre-existing deficits in both 
MNCV and SNCV were partially reversed.  Interestingly, the improvement in SNCV and 
thermal hypoalgesia in erlotinib-treated diabetic Swiss Webster mice was not observed in our 
78 
 
previous study using C57BL/6 mice [143].  Whether this observation is attributable to 
differences between the mouse strains is unclear.  Nonetheless, these data support that Erb B2 
signaling may contribute to glial cell dysfunction in DPN. 
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Figure 3.3.1: Inhibition of Erb B2 receptors partially attenuated sensory deficits in diabetic 
Swiss Webster mice.  Swiss Webster mice were rendered diabetic and after two weeks of 
diabetes, mechanical (A) and thermal sensitivity (B) were assessed weekly (*, p < 0.05 for 
STZ+Veh vs. time-matched Veh+Veh; ^, p < 0.05 for STZ+Erl vs. time-matched STZ+Veh).  At 
13 weeks of diabetes, animals were given vehicle or 25 mg/kg erlotinib once per week for 4 
weeks (solid arrow) and then twice per week (dashed arrow) for the final four weeks (n = 8-12 
per group).  Erlotinib significantly improved mechanical and thermal sensitivity compared to 
vehicle treated diabetic mice. 
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Figure 3.3.2: Inhibition of Erb B2 receptors partially restored decreased nerve conduction 
velocity in diabetic Swiss Webster mice.  Swiss Webster mice were rendered diabetic and 
assessment of MNCV (A) and SNCV (B) in a subgroup of animals (n = 4 per group) after 12 
weeks of diabetes confirmed the onset of nerve dysfunction prior to drug treatment.  At 13 weeks 
of diabetes, animals were given vehicle or 25 mg/kg erlotinib once per week for 4 weeks and 
then twice per week for the final four weeks (n = 8-12 per group).  Erlotinib significantly 
restored the nerve function in both MNCV and SNCV compared to vehicle treated diabetic mice. 
 
Measurements of IENFD is emerging as a highly sensitive technique for diagnosing and 
staging the disease status of small fiber neuropathy in patients [133] and animal models [134, 
135].  We collected the plantar surface of the hind paws before and after erlotinib treatments and 
stained the nerve fibers with an antibody against PGP 9.5, which is a cytosolic ubiquitin C-
terminal hydroxylase specifically expressed in neurons.  The PGP 9.5-positive nerve fibers that 
crossed the epidermal/dermal junction were counted to quantify distal nerve innervation (Figure 
3.3.3).  As anticipated, 12 weeks of diabetes significantly decreased IENFD (20%) but fiber loss 
was not significantly greater after 21 weeks of diabetes (27%).  However, erlotinib treatment 
partially reversed the diabetes-induced loss of the largely unmyelinated intra-epidermal nerve 
fibers.  Though the increase in IENFD in erlotinib-treated diabetic mice may contribute to the 
enhanced sensitivity to noxious thermal stimuli, improved thermal sensitivity can occur even in 
the absence of an increase in epidermal fibers [135].  Together, these data support that altered 
activity of Erb B2 signaling may be a contributing factor underlying diabetes-induced peripheral 
nerve damage in both myelinated and unmyelinated fibers in Swiss Webster mice. 
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Figure 3.3.3: Inhibition of Erb B2 receptors improved IENFD in diabetic Swiss Webster 
mice.  Footpad samples were collected from the plantar surface of the hind paws after 12 (n = 4 
per group) and 21 weeks (n = 6–8 per group) of treatment.  (A): Representative images of 
IENFD in non-diabetic (Veh) and diabetic (STZ) mice treated with vehicle (Veh) or erlotinib 
(Erl).  Nerve fibers immunopositive for PGP 9.5 are stained red by the chromagen (arrows) and 
epidermal cells were stained purple by hematoxylin.  (B): Quantification demonstrated a 
significant loss of nerve innervation in diabetic mice prior to drug administration and erlotinib 
treatment induced a partial recovery in fiber loss. 
 
After 12 and 21 weeks of diabetes, FBG levels and HbA1c were increased, whereas body 
weight was decreased in diabetic Swiss Webster mice compared to age-matched, vehicle-treated 
control mice (Table 3.3.1).  Erlotinib treatment did not affect glucose level or body weight 
compared to vehicle-treated diabetic mice.  These results indicate that the effects of erlotinib on 
improving the diabetes-induced nerve deficits in both myelinated and unmyelinated nerve fibers 
were not due to correction of the systemic hyperglycemia, consistent with our previous 
observation in diabetic C57BL/6 mice [143]. 
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Table 3.3.1: Body weights, FBG and HbA1c values from the Swiss Webster mice 
Week Treatment FBG 
(mg/dl) 
Weight (g) (n) HbA1c (%) (n) 
Week 12 
Veh 112 ± 21 37.2 ± 5.4 10 5.0 ± 0.4 6 
STZ 595 ± 12* 30.6 ± 3.7* 11 12.9 ± 0.2* 7 
Week 21 
Veh+Veh 121 ± 26 42.6 ± 5.4 8 5.1 ± 0.1 3 
Veh+Erl 104 ± 17 43.4 ± 2.7 8 5.0 ± 0.2 3 
STZ+Veh 545 ±106* 34.5 ± 3.5* 8 10.2 ± 1.7* 4 
STZ+Erl 584 ± 40# 37.0 ± 5.5
# 6 11.4 ± 1.1# 4 
*, p < 0.05 vs. Veh or Veh+Veh; #, p < 0.05 vs. Veh+Erlotinib (Erl) 
 
3.4. Diabetes Differentially Alters the Expression of NRG1 Isoforms in Peripheral 
Nerves 
3.4.1. Expression Levels of NRG1 Type III were Decreased in Diabetic Peripheral Nerves 
Though aberrant Erb B2 activity can contribute to DPN, it remains unknown whether this 
may be associated with changes in the expression of NRG1 isoforms which regulate Schwann 
cell differentiation or dedifferentiation.  In order to evaluate the changes of NRG1 Type III 
expression along with the progression of diabetes, we sacrificed several mice from both diabetic 
and non-diabetic groups after various durations of diabetes.  Peripheral nerves were isolated from 
control and diabetic mice and protein lysates were separated by SDS-PAGE and probed with two 
different NRG1 Type III antibodies (discussed in Materials and Methods). 
In a preliminary study, C57BL/6 mice were rendered diabetic and peripheral nerves were 
collected after 9 weeks of diabetes.  Immunoblot analysis showed that NRG1 Type III levels 
were more robustly reduced in diabetic tibial versus sciatic nerves, which might be attributed to 
the more distal location of tibial nerves in the PNS (Figure 3.4.1.1).  Since DPN progresses in a 
distal-to-proximal manner, it is possible that 9 weeks of diabetes is sufficient to alter NRG1 Type 
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III levels in the distal tibial nerves, but has a relatively minor effect on proximal sciatic nerves.  
However, during the time course in this study, we did not detect any changes of NRG1 Type III 
expression in sural nerves.  Combined with the previous observation that SNCV did not change 
in short-term diabetic C57BL/6 mice, these data suggest that hyperglycemia may affect 
myelinated nerves (such as sciatic and tibial nerves) earlier and greater than unmyelinated nerves 
(such as sural nerves).  Given the function of axonal NRG1 Type III to promote Schwann cell 
differentiation and myelination, these data suggest that diabetes may compromise myelination by 
decreasing NRG1 Type III levels, especially in myelinated nerves. 
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Figure 3.4.1.1: NRG1 Type III levels were decreased in sciatic nerves and tibial nerves 
after 9 weeks of diabetes in C57BL/6 mice.  Wild-type C57BL/6 mice were rendered diabetic 
for 9 weeks.  Sciatic nerves (A) and tibial nerves (B) were isolated (n = 4-5 per group).  Protein 
lysates were prepared and NRG1 Type III levels were determined by immunoblot analysis using 
two antibodies.  (C): Bands were quantified, NRG1 Type III levels were normalized to β-actin 
and expressed as a fold of the levels in control nerves (*, p < 0.05; **, p < 0.01 for STZ vs. Veh). 
 
Similarly, immunoblot analysis showed that 9 weeks of diabetes induced a significant 
decrease in NRG1 Type III levels in diabetic sciatic, tibial and sural nerves from the Swiss 
Webster mice.  This result was also confirmed by both antibodies (Figure 3.4.1.2).  Consistent 
with the results obtained in the C57BL/6 mice, diabetic tibial nerves showed the maximal 
magnitude of reduction in NRG1 Type III levels in the three types of peripheral nerves.  
Interestingly, we detected a significant decrease in NRG1 Type III expression levels in diabetic 
sural nerves after 9 weeks of diabetes, which was not observed in 9-week diabetic C57BL/6 
mice.  These data indicate that hyperglycemia in diabetic Swiss Webster mice may cause more 
nerve damage and extend its effects to unmyelinated nerve fibers. 
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Figure 3.4.1.2: NRG1 Type III levels were decreased in sciatic nerves, tibial nerves and 
sural nerves after 9 weeks of diabetes in Swiss Webster mice.  Swiss Webster mice were 
rendered diabetic for 9 weeks.  Sciatic nerves (A), tibial nerves (B) and sural nerves (C) were 
isolated (n = 7-8 per group).  Protein lysates were prepared and NRG1 Type III levels were 
determined by immunoblot using the two antibodies.  (D): Bands were quantified, NRG1 Type 
III levels were normalized to β-actin and expressed as a fold of the levels in control nerves (*, p 
< 0.05; **, p < 0.01; ***, p < 0.001 for STZ vs. Veh). 
 
With disease progression, 12 weeks (Figure 3.4.1.3) and 16 weeks (Figure 3.4.1.4) of 
diabetes induced a considerable decrease in NRG1 Type III expression levels in tibial and sural 
nerves, confirmed by two antibodies.  Results in the 16 sciatic nerve samples were inconsistent 
between the antibodies but the origin of this discrepancy could not be ascertained.  Nonetheless, 
these data suggest that chronic hyperglycemia could mitigate the expression of the pro-
myelinating isoform (Type III) of NRG1 family in both myelinated and unmyelinated nerve 
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fibers. This decrease might be associated with sensory hypoalgesia and the comprised nerve 
function (decreased MNCV and SNCV). 
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Figure 3.4.1.3: NRG1 Type III levels were decreased in sciatic nerves, tibial nerves and 
sural nerves after 12 weeks of diabetes in Swiss Webster mice.  Swiss Webster mice were 
rendered diabetic for 12 weeks.  Sciatic nerves (A), tibial nerves (B) and sural nerves (C) were 
isolated (n = 5-7 per group).  Protein lysates were prepared and NRG1 Type III levels were 
determined by immunoblot analysis using the two antibodies.  (D): Bands were quantified, 
NRG1 Type III levels were normalized to β-actin and expressed as a fold of the levels in control 
nerves (*, p < 0.05; **, p < 0.01; ***, p < 0.001 for STZ vs. Veh). 
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Figure 3.4.1.4: NRG1 Type III levels were decreased in sciatic nerves, tibial nerves and 
sural nerves after 16 weeks of diabetes in Swiss Webster mice.  Swiss Webster mice were 
rendered diabetic for 16 weeks. Sciatic nerves (A), tibial nerves (B) and sural nerves (C) were 
isolated (n = 7-9 per group).  Protein lysates were prepared and NRG1 Type III levels were 
determined by immunoblot analysis using the two antibodies.  (D): Bands were quantified, 
NRG1 Type III levels were normalized to β-actin and expressed as a fold of the levels in control 
nerves (*, p < 0.05; **, p < 0.01 for STZ vs. Veh). 
 
3.4.2. Expression Levels of NRG1 Type I were Increased in Diabetic Peripheral Nerves 
Though a significant decrease in NRG1 Type III levels in diabetic peripheral nerves were 
observed, a lower ligand expression (NRG1 Type III in this case) could not be the mechanism 
underlying enhanced activation of Erb B2.  Therefore, we evaluated the changes of another 
isoform in the NRG1 family, NRG1 Type I.  The expression levels were detected by an Abcam 
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NRG1 Type I antibody against the peptide sequence near N-terminus of NRG1 Type I, which 
differs from N-terminal fragments of NRG1 Type III. 
Nine weeks of diabetes induced a moderate but significant increase (1.5-fold) in NRG1 Type 
I expression levels in sural nerves (Figure 3.4.2.1), but not in sciatic or tibial nerves.  With 
disease progression, the expression of NRG1 Type I further increased (2.5-fold) in sural nerves 
after 12 weeks of diabetes (Figure 3.4.2.2).  In addition, a 2.3-fold increase of NRG1 Type I was 
detected in diabetic tibial nerves after 12 weeks of diabetes, but no significant change was 
observed in diabetic sciatic nerves. 
Though we did not detect significant changes of NRG1 Type I expression after 16 weeks of 
diabetes, the transient increase in NRG1 Type I expression levels after 9 weeks and 12 weeks of 
diabetes might be one of the underlying mechanisms to over-activate Erb B2 receptors in 
diabetic nerves.  In addition, both diabetic sural nerves and tibial nerves have a significant 
induction in NRG1 Type I expression, but not in diabetic sciatic nerves.  It is possible that thinly-
myelinated and unmyelinated nerve fibers (sural and tibial nerves) are more vulnerable to 
diabetes-induced changes of NRG1 Type I expression levels.  Given the demyelinating functions 
of NRG1 Type I in vitro, enhanced NRG1 Type I expression might contribute to diabetes-
induced glial dedifferentiation and eventually demyelination in vivo, though normal myelin 
thickness of sciatic nerves was observed in NRG1 Type I conditional overexpressing mice 
(under the control of Thy 1.2 promoter, which is active in postnatal motoneurons and DRG 
neurons). 
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Figure 3.4.2.1: NRG1 Type I levels were increased in sural nerves after 9 weeks of diabetes 
in Swiss Webster mice.  Swiss Webster mice were rendered diabetic for 9 weeks.  Sciatic nerves 
(A), tibial nerves (B) and sural nerves (C) were isolated (n = 6-7 per group).  Protein lysates 
were prepared and NRG1 Type I levels were determined by immunoblot analysis.  (D): Bands 
were quantified, NRG1 Type I levels were normalized to β-actin and expressed as a fold of the 
levels in control nerves (*, p < 0.05 for STZ vs. Veh). 
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Figure 3.4.2.2: NRG1 Type I levels were increased in sural nerves and tibial nerves after 12 
weeks of diabetes in Swiss Webster mice.  Swiss Webster mice were rendered diabetic for 12 
weeks.  Sciatic nerves (A), tibial nerves (B) and sural nerves (C) were isolated (n = 6-7 per 
group).  Protein lysates were prepared and NRG1 Type I levels were determined by immunoblot 
analysis.  (D): Bands were quantified, NRG1 Type I levels were normalized to β-actin and 
expressed as a fold of the levels in control nerves (*, p < 0.05; **, p < 0.01 for STZ vs. Veh). 
 
Together with the observation of decreased NRG1 Type III in diabetic peripheral nerves, 
these data suggested that diabetes could differentially alter the expression of NRG1 isoforms by 
decreasing the pro-myelination isoform (NRG1 Type III) and increasing a demyelinating isoform 
(NRG1 Type I).  This disrupted balance between NRG1 Type III and NRG1 Type I in both 
myelinated and unmyelinated nerve fibers could contribute to the neuropathic symptoms 
(sensory deficits, nerve dysfunction and loss of fiber innervation) observed in diabetic Swiss 
Webster mice.  However, after 21 weeks of diabetes with 8 weeks of erlotinib treatments, we did 
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not detect any changes in expression levels of NRG1 isoforms either by chronic hyperglycemia 
or erlotinib.  Whether this lack of change is attributed to potential metabolic mechanisms or 
compensation from the growth factor interaction remains unclear. 
 
3.5. Diabetes Decreases Erbin Expression and Increases p42/p44 MAPK Activity 
Given the negative regulation of erbin on myelination and Erb B2 receptor activation, we 
hypothesized that a decrease in erbin expression may contribute to the potential overactivation of 
Erb B2 signaling and demyelination in diabetic mice.  Erbin is an Erb B2-interacting protein that 
can function as a negative regulator of receptor signaling, in part by inhibiting p42/p44 MAPK 
activity [288].  Thus, a decrease in erbin expression may also contribute to potential 
dysregulation of Erb B2 signaling in diabetic nerve.  Diabetic sciatic nerve showed a decreased 
expression of erbin after 12 and 16 weeks of diabetes (Figure 3.5.1). 
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Figure 3.5.1: Erbin levels were decreased in sciatic nerves in diabetic Swiss Webster mice.  
Swiss Webster mice were rendered diabetic.  Sciatic nerves were isolated after 9 weeks (A), 12 
weeks (B) and 16 weeks (C) of diabetes (n = 6-9 per group).  Protein lysates were prepared and 
Erbin levels were determined by immunoblot analysis.  (D): Bands were quantified, Erbin levels 
were normalized to β-actin and expressed as a fold of the levels in control nerves (**, p < 0.01 
for STZ vs. Veh). 
 
Considering the inhibitory effects of erbin on p42/p44 MAPK (ERK) pathway, we measured 
p42/p44 MAPK activity by immunoblot analysis.  Phospho-p42/p44 MAPK and total-p42/p44 
MAPK levels were normalized to corresponding β-actin levels.  Then the p42/p44 MAPK 
activities were determined by the ratio of phospho-p42/p44 MAPK divided by total-p42/p44 
MAPK expression.  Enhanced p42/p44 MAPK activities were only detected in sciatic nerves 
after 16 weeks of diabetes (Figure 3.5.2). 
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Figure 3.5.2: p42/p44 MAPK activities were enhanced in sciatic nerves after 16 weeks of 
diabetes.  Sciatic nerves were isolated control and diabetic mice (n = 8-9 per group).  Protein 
lysates were prepared and p42/p44 MAPK activities were determined by immunoblot.  
Quantification demonstrated a significant increase in p42/p44 MAPK activation at 16 weeks (**, 
p < 0.01 for STZ vs. Veh). 
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With disease progression, we also observed a significant increase in p42/p44 MAPK 
activities in both sciatic (Figure 3.5.3 B) and sural nerves (Figure 3.5.4 B), whereas erbin levels 
were decreased only in sural nerves (Figure 3.5.4 A) after 21 weeks of diabetes.  In addition, 8 
weeks of erlotinib treatment completely suppressed the extent of p42/p44 MAPK 
phosphorylation in diabetic sural nerve (Figure 3.5.4 B), but this did not reach significance in 
diabetic sciatic nerve (Figure 3.5.3 B).  Longer periods and a higher or more frequent dose of 
erlotinib treatment might extend the inhibitory effects p42/p44 MAPK activity in sciatic nerve 
and induce greater recovery.  However, in spite of the complete suppression on p42/p44 MAPK 
activation by erlotinib treatment, this was associated with only a partial recovery in the 
physiologic measures of DPN. Thus, monotherapy targeting the MAPK pathway may not be 
sufficient to fully reverse the pathophysiological sensory deficits in DPN patients. 
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Figure 3.5.3: Diabetes induced p42/p44 MAPK pathway activation in sciatic nerves.  Swiss 
Webster mice were rendered diabetic.  Sciatic nerves were isolated from vehicle or erlotinib-
treated control and diabetic mice (n = 3-4 per group) after 21 weeks of diabetes with 8 weeks of 
erlotinib treatments.  Protein lysates were prepared and erbin levels (A) and p42/p44 MAPK 
levels (B) were determined by immunoblot.  (C): Quantification demonstrated an increase in 
p42/p44 MAPK activation in vehicle-treated diabetic mice (*, p < 0.05). 
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Figure 3.5.4: Inhibition of Erb B2 with Erlotinib suppressed diabetes-induced p42/p44 
MAPK pathway activation in sural nerves.  Swiss Webster mice were rendered diabetic.  
Sural nerves were isolated from vehicle or erlotinib-treated control and diabetic mice (n = 3–4 
per group) after 21 weeks of diabetes with 8 weeks of erlotinib treatments.  Protein lysates were 
prepared and erbin levels (A) and p42/p44 MAPK levels (B) were determined by immunoblot.  
(C): Quantification demonstrated a significant decrease of Erbin and an increase in p42/p44 
MAPK activation in vehicle-treated diabetic mice.  Erlotinib treatment suppressed p42/p44 
MAPK activation in Erlotinib-treated diabetic mice (*, p < 0.05; **, p < 0.01). 
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Chapter 4: Discussion 
4.1. Activation of NRG1-Erb B2 Signaling in Diabetic Peripheral Neuropathy 
Though it has been established that NRG1-Erb B signaling plays an essential role in the 
development of the PNS and the regeneration after nerve injury, little is known about whether 
diabetes may alter NRG1-Erb B signaling in peripheral nerve.  We were the first to report that a 
transient aberrant activation of Erb B2 receptors is one of the contributing factors to the 
development of DPN, since 3-week treatments of Erb B2 receptor inhibitor erlotinib fully 
reversed the mechanical hypoalgesia and MNCV deficits after 12 weeks of diabetes in C57BL/6 
mice [143].  The current study used outbred Swiss Webster mice that develop more robust 
diabetic neuropathy, especially in myelinated nerve fibers.  Though we only observed a partial 
recovery in mechanical hypoalgesia and MNCV deficits after 8 weeks of erlotinib treatments, it 
is important to note that we detected a significant improvement in thermal sensitivity and SNCV, 
which has not been reported in the previous study [143].  In addition, erlotinib treatments 
induced a greater recovery in thermal sensitivity and SNCV (70%) compared to that in 
mechanical sensitivity (56%) and MNCV (39%).  Whether this observation is attributable to 
differences between the mouse strains is unclear.  Nonetheless, these data demonstrate that 
NRG1-Erb B2 signaling activation may contribute to Schwann cell dysfunction in DPN. 
More importantly, the current study is the first to demonstrate that diabetes can alter the 
expression of NRG1 isoforms in peripheral nerves.  While we observed a reduction in NRG1 
Type III levels in diabetic sciatic, tibial and sural nerves, the level of NRG1 Type I was 
increased in tibial and sural nerves after 9-12 weeks of diabetes.  Since inhibition of Erb B2 
signaling with erlotinib partially reversed the sensory deficits associated with prolonged diabetes, 
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the elevated expression of NRG1 Type I in diabetic nerves might be sufficient to induce Erb B2 
receptor activation and contribute to the progression of DPN.  Moreover, the decreased NRG1 
Type III and increased NRG1 Type I expression observed in diabetic tibial and sural nerves (but 
not in diabetic sciatic nerves) implies that distal and more thinly myelinated fibers may be more 
susceptible to early disruption of NRG1 signaling.  This would be consistent with recent results 
showing a greater severity of oxidative stress in distal sural nerve compared to sciatic nerve 
[302]. 
NRG1 Type III is a membrane-anchored precursor protein which needs to be proteolytically 
processed to become an active signaling molecule.  The β-secretase BACE1 and the α-secretase 
TACE are two enzymes that process NRG1.  NRG1 Type III processed by BACE1 produces a 
membrane-associated, N-terminal fragment that promotes myelination [269], whereas TACE 
cleaves NRG1 Type III within the EGF-like domain and inactivates it, resulting in 
hypomyelination [274].  BACE cleavage also produces the C-terminal fragment which can be 
degraded by γ-secretase.  Though the C-terminal fragment is not necessary for myelination, it 
may be translocated to the nucleus of neurons and can repress apoptosis and promote survival 
[275].  Diabetes-induced changes in the expression of NRG1 Type III produced by BACE 
cleavage were verified using two antibodies which targeted either the CRD located within the 
~75 kDa N-terminal fragment or an epitope within the C-terminal fragment (discussed in 
Materials and Methods).  Interestingly, we did not consistently observe the presence of 
unprocessed NRG1 Type III in nerves from either control or diabetic mice.  This suggests that 
the decrease in the expression of the N- and C-terminal fragments of NRG1 Type III were not 
due to a decrease in BACE levels or dysfunction of proteolytic processing.  Since transcriptional 
and/or translational modifications play a critical role of regulating the protein expression of 
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neurotrophins, it may also occur to NRGs and changes in the rate of transcription and/or 
translation could contribute to the decrease in NRG1 Type III.  However, we also observed an 
increase in NRG1 Type I in diabetic nerves.  Since both isoforms are the product of alternative 
splicing of a single transcript, it is possible that diabetes-induced changes in mRNA processing 
may alter the isoform expression pattern.  In this regard, diabetes has been shown to alter 
expression of transcriptional variants of the Slo gene that may contribute to erectile dysfunction 
[303].  However, diabetes may have tissue specific effects on the expression of NRG1 isoforms.  
For example, the levels of NRG1 Type I were decreased in diabetic rats with cardiomyopathy 
[304] and impaired NRG1-Erb B signaling may contribute to the pathogenesis of diabetic 
cardiomyopathy, increasing susceptibility to heart failure [305]. 
The degeneration of sensory neurons in DPN is clearly associated with an alteration in 
neurotrophic support and disrupted NRG1-Erb B2 signaling, presumably in Schwann cells, may 
be interconnected with altered neurotrophism.  BDNF is released from Schwann cells and  its 
expression is decreased in diabetic rats [227].  Treatment with BDNF prevented nerve 
conduction slowing and damage to large motor fibers [228].  A clear relationship exists between 
BDNF and NRG1 signaling since BDNF can stimulate the secretion of soluble forms of NRG1 
[239], whereas transgenic blockade of endogenous Erb B2 via expression of a DN-Erb B4 in 
non-myelinating Schwann cells was sufficient to decrease the expression of BDNF [250].  In 
addition, NT-3 and ciliary neurotrophic factor (CNTF) stimulate proliferation of DRG progenitor 
cells through inducing NRG1 secretion in a dose-dependent manner [306].  These data indicate 
that a tight relationship exists between neurotrophins and NRGs.  Though it remains unclear 
whether changes in neurotrophin levels may have contributed to the altered expression of NRG1 
isoforms observed in diabetic nerves in the current study, elucidating the effect of diabetes on the 
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activity of neurotrophins and NRGs in dedifferentiating and regenerating Schwann cells may 
provide fundamental insight into the potential for pharmacologically regulating Erb B2 signaling 
at specific disease stages to improve nerve function.  Lastly, recent data also suggests that axonal 
expression of NRG1 Type III can negatively regulate the expression of Schwann cell-derived 
NRG1 Type I [307].  Although these results were obtained in the context of a decrease in NRG1 
Type III due to axonal loss following nerve crush, axonal loss is not a hallmark of the rather 
early stage of DPN modeled in our study.  Thus, a diabetes-induced alteration in the expression 
of NRG1 Type III without frank axonal loss may be sufficient to promote the expression of 
NRG1 Type I.  However, additional work is required to determine if the negative regulation of 
NRG1 Type I expression by axonal NRG1 Type III may be recapitulated following a peripheral 
nerve injury that is solely metabolic. 
4.2. Role of Erbin in Diabetic Peripheral Neuropathy 
Erbin plays an important role in myelination functions since erbin null mice have a decrease 
in Erb B2 levels and NRG1-induced myelination [290].  Erbin also serves as a negative regulator 
of p42/p44 MAPK signaling by disrupting the interaction between Ras and Raf [288, 308].  
Consistent with this relationship, diabetes decreased erbin levels in sciatic and sural nerves and 
this correlated with an increase in the activity of p42/p44 MAPK.  Although erlotinib treatment 
inhibited the activation of p42/p44 MAPK in sural nerves without increasing erbin expression, it 
is not possible to directly link this change in MAPK activity to the improved sensory endpoints 
following erlotinib treatment since the drug would be expected to blunt all signaling through Erb 
B2.  Though activation of the MAPK pathway has been associated with demyelination [258, 
309], myelin loss is not a hallmark of DPN in rodent models.  Therefore, the activation of this 
pathway is either of insufficient magnitude and duration to promote demyelination in rodent 
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nerve or contributes to other aspects of DPN.  However, the contribution of p42/p44 MAPK 
activity to DPN in both rodent and human DPN is unclear and these enzymes showed variable 
activation in sural nerve biopsies obtained from diabetic patients undergoing amputations [310]. 
In contrast, DRG/Schwann cell co-cultures provide a well-characterized in vitro model to 
investigate the function of erbin and downstream p42/p44 MAPK pathway during the 
developmental and myelinating stages.  Myelinated DRG/Schwann cell co-cultures were 
prepared and infected with an erbin shRNA -expressing lenti-virus for 16 hrs.  Cell lysates were 
collected 48 hrs after infection and protein lysates were separated by SDS-PAGE. 
Though studies have shown that NRG1-Erb B signaling is mostly dispensable for 
maintenance of myelinated peripheral nerves [276], immunoblot analysis (Figure 4.2.1) showed 
that depletion of erbin in DRG/Schwann cell co-culture induced a remarkable reduction in P0 
levels in a dose-dependent manner.  Though erbin has been recognized as binding partner to 
various proteins and is involved in protein-protein interactions, whether erbin could directly bind 
to and regulate myelin proteins such as myelin basic protein (MBP) or P0 needs further 
confirmation.  In addition, we previously demonstrated that hyperglycemia sensitizes the 
myelinated DRG/Schwann cell co-cultures to NRG1 Type I-induced demyelination [299].  
However, it remains unknown whether this exacerbated demyelination is associated with 
hyperglycemia-induced downregulation of erbin and corresponding p42/p44 MAPK activation. 
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Figure 4.2.1: Erbin is necessary for maintenance of myelination in fully myelinated 
DRG/Schwann cell co-cultures.  Mouse DRG/Schwann cell co-cultures were prepared and 
infected with vehicle (NT), control lacZ-shRNA and two colons of erbin-shRNA for 16 hrs.  
Protein lysates were collected 48 hrs after infection and were separated by SDS-PAGE.  
Immunoblot analysis were quantified, erbin and P0 levels were normalized to β-actin and 
expressed as a fold of the levels in non-treated cells 
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In summary, we propose that impaired NRG1-Erb B2 signaling contributed to the onset and 
progression of DPN.  Hyperglycemia differentially altered the expression of NRG1 isoforms.  
While a decreased pro-myelinating NRG1 Type III expression in diabetic nerves may 
compromise nerve function and contribute to sensory deficits, an increased expression of 
demyelinating NRG1 Type I in diabetic tibial and sural nerves may be sufficient to alter the 
activation of Erb B2 receptor.  Furthermore, erbin levels were downregulated in diabetic sciatic 
nerves and this corresponded with an increase in p42/p44 MAPK pathway activity, which could 
promote the Schwann cell dedifferentiation and demyelination.  Inhibition of Erb B2 signaling 
with erlotinib partially reversed several pathophysiologic aspects of DPN including a 
pronounced sensory hypoalgesia, nerve conduction velocity deficits and the loss of epidermal 
nerve fiber innervation (Figure 4.2.2). 
 
Figure 4.2.2: Proposed mechanism that is associated with the enhanced Erb B2 activation 
and erlotinib-mediated recovery in diabetic peripheral neuropathy.  Hyperglycemia 
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differentially alters the expression of NRG1 isoforms and downregulates erbin levels, resulting 
in an increase in p42/p44 MAPK pathway activation, which could promote the Schwann cell 
dedifferentiation and contribute to the nerve dysfunction and demyelination.  Erb B2 receptor 
inhibitor erlotinib reveres pathophysiologic deficits and suppressed p42/p44 MAPK activation in 
diabetic peripheral neuropathy. 
 
4.3. Mitochondrial Dysfunction and NRG1-Erb B2 Signaling 
Mitochondria is the key organelle regulating cellular energy production to adapt to 
fluctuating APT demands.  In diabetes, excessive glucose is metabolized through glycolysis, the 
TCA cycle and oxidative phosphorylation, producing an over-abundance of ROS.  In particular, 
glucose uptake in neurons is mediated primarily by GLUT-3, is insulin-independent and a high 
extracellular glucose concentration will distribute glucose equally across the plasma membrane 
driven via equilibrative transport.  In addition, hyperglycemia-driven over activation of cellular 
signaling pathways such as AGE formation, enhanced polyol pathway and increased PKC 
activation could further contribute to ROS generation.  Accumulated ROS can impair 
mitochondrial function by damaging mitochondrial DNA, proteins and membrane potential.  
Many studies have shown that the mitochondrial inner membrane potential of adult sensory 
neurons from STZ-induced diabetic animals was depolarized [150, 311], suggesting deficits in 
mitochondrial function.  Consistent with these data, we also observed a decrease in 
mitochondrial bioenergetics in sensory neurons obtained from diabetic Swiss Webster mice. 
With the introduction of the Seahorse Bioscience Analyzer, it is feasible to investigate 
neuronal bioenergetics in cultured neurons.  Diabetic Swiss Webster mice showed an impaired 
mitochondrial respiration only after 16 weeks of diabetes (Figure 4.3.1) [312].  This impairment 
was not due to changes of mitochondrial number or mass.  However, whether the late onset of 
impaired mitochondrial bioenergetics is associated with the enhanced MAPK activation observed 
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in sciatic nerves after 16 weeks of diabetes remains unclear.  Nonetheless, these data suggest that 
reduced respiratory capacity, especially in neurons, limits their adaptive ability to meet energetic 
demand and renders the cells more susceptible to secondary stress such as the overproduction of 
ROS.  The exhausted ATP supply in the distal nerve compartment could contribute to defective 
axon regeneration and nerve fiber re-innervation.  In addition, unmyelinated axons have been 
found to be more energetically demanding than myelinated axons [313]. 
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Figure 4.3.1:  Diabetes induced the onset of mitochondrial bioenergetic deficits in DRG 
neurons.  Swiss Webster mice were rendered diabetic.  Adult lumber DRG neurons (L4-L6) 
were collected after 9, 12, 16 and 21 weeks of diabetes.  Spare respiratory capacity (SRC) was 
measured by an XF96 Extracellular Flux Analyzer.  After 16 weeks of diabetes, SRC was 
significantly decreased in diabetic DRG neurons compared to time-matched non-diabetic 
controls (*, p < 0.05 for STZ vs. Veh). 
 
Given the tight interrelationship between Schwann cells and neurons in the PNS, Schwann 
cell abnormalities may also contribute to mitochondrial dysfunction in DPN.  However, little is 
known about the Schwann cell mitochondrial deficits in DPN.  Enlarged mitochondria in 
Schwann cells of both myelinated and unmyelinated nerve fibers were observed in sural nerve 
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biopsy samples from diabetic patients with progressive neuropathy [314].  In addition, the 
transgenic mice (Tfam-SCKO) with Schwann cell-specific deletion of mitochondrial 
transcription factor A (Tfam) developed a progressive peripheral neuropathy including nerve 
conduction velocity deficits and extensive muscle denervation [315].  These transgenic mice also 
have axonal degeneration with early preferential loss of small unmyelinated fibers, which was 
followed by prominent demyelination of large nerve fibers.  The mitochondria isolated from 
sciatic nerves in Tfam-SCKO mice showed a 60% decrease in the activity of cytochrome oxidase 
that is encoded by mitochondrial DNA, but normal activity of succinate dehydrogenase that is 
encoded by nuclear DNA.  Surprisingly, this severe mitochondrial DNA depletion and 
respiratory chain abnormalities in Tfam-SCKO mice was not associated with Schwann cell 
proliferation or survival.  Furthermore, our lab previously found that hyperglycemia increased 
the expression of a range of proteins that contributed to mitochondrial dysfunction and 
compromised the efficiency of mitochondrial respiration in cultured primary Schwann cells 
[316].  These data suggest mitochondrial function in both Schwann cell and neurons is necessary 
to maintain the axon-glia integral relationship. 
Though exogenous Schwann cell-derived neurotrophins (NGF, IGF-I and NT-3) prevent 
depolarization of the mitochondrial inner membrane potential in diabetic sensory neurons, 
whether NRGs could support mitochondrial integrity in Schwann cells remains unclear.  
Therefore, we treated cultured primary Schwann cell with low glucose (5.5 mmol/L) or high 
glucose (25 mmol/L) for 6 days and sub-groups were treated with 10 ng/ml NRG1 Type I or 10 
ng/ml NRG1 Type III during the last 24 hours.  Mitochondrial bioenergetics were measured 
using the Seahorse Bioscience XF96 Analyzer.  Interestingly, both NRG1 Type I and NRG1 
Type III increased SRC to a similar extent, compared to control in low glucose medium (Figure 
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4.3.2).  However, hyperglycemia significantly impaired NRG1 Type III-induced but not NRG1 
Type I-induced improvement in mitochondrial bioenergetics.  Similarly, one group found a 
synergistic effect of increasing in mitochondrial density by NRG1 Type I (20 ng/ml) and IGF 
(100 ng/ml) in Schwann cell cultures [317].  Whether exogenous NRG1 Type I treatment 
stimulated endogenous IGF secretion in our study needs further confirmation.  In addition, 
hyperglycemia specifically impaired NRG1 Type III-increased OCR and SRC.  More studies are 
needed to investigate whether NRG1 Type I and NRG1 Type III might enhance mitochondrial 
bioenergetics through different mechanisms and whether the pathway stimulated by NRG1 Type 
III is more susceptible to hyperglycemia. 
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Figure 4.3.2: Hyperglycemia impaired NRG1 Type III-induced but not NRG1 Type I-
induced increase in mitochondrial bioenergetics in cultured primary Schwann cells.  
Schwann cell cultures were treated with low glucose (LG) or high glucose (HG) medium for 6 
days and sub-groups were treated with 10 ng/ml NRG1 Type I or 10 ng/ml NRG1 Type III for 24 
hours.  Oxygen consumption rate (OCR) and Spare respiratory capacity (SRC) were measured by 
an XF96 Extracellular Flux Analyzer.  Bothe OCR and SRC were increased by the treatment of 
both NRG1 isoforms.  However, hyperglycemia significantly impaired NRG1 Type III-induced 
but not NRG1 Type I-induced increase in mitochondrial bioenergetics (*, p < 0.05 vs. LG; ^, p < 
0.05 vs. HG; #, p < 0.05 vs. NRG1 Type III). 
 
Upon NRG1 stimulation, Erb B2 receptors have been shown to translocate to mitochondrial 
through associating with the mitochondrial heat shock protein 70 (mtHSP70) in Erb B2-postive 
cancer cells.  This translocation negatively regulated mitochondrial respiratory function and 
rendered the cancer cells more resistant to ErbB2-targeting antibody trastuzumab [318].  To 
determine if a similar translocation event may occur in Schwann cells, Erb B2 receptor levels 
were measured in a mitochondrial fraction isolated from Schwann cell treated with 10 ng/ml 
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NRG1 Type I.  In contrast to the results in cancer cells, immunoblot analysis (Figure 4.3.3) 
showed a decrease in Erb B2 receptor levels upon NRG1 Type I treatment in both mitochondrial 
and cytosolic fractions.  A lower level of Erb B2 receptors in mitochondria might contribute to a 
higher mitochondrial respiratory function.  However, we detected a time-dependent decline in 
NRG1 Type I-activated p42/p44 MPAK pathway (Figure 4.3.4), suggesting that the signaling 
cascades activated by NRG1 Type I differ between acute and prolonged treatment.  Therefore, it 
is not possible to directly link the decrease in mitochondrial Erb B2 receptor induced by 1 hour 
NRG1 Type I treatment to the increased mitochondrial bioenergetics induced by 24 hours NRG1 
Type I treatment.  Surprisingly, we detected a predominant expression of Erb B2 receptors in 
mitochondrial fraction compared to the cytosolic fraction in untreated cells.  This suggests that 
the presence of ligand recruits the receptor to the plasma membrane and initiates the signaling 
cascades.  Furthermore, Schwann cells have been hypothesized to be mainly glycolytic and rely 
on non-oxidative catabolism of glucose to meet their energy needs [319].  Whether this 
enrichment of Erb B2 receptors in mitochondria at basal level contributes to minimize 
mitochondrial activity is unclear. 
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Figure 4.3.3: Erb B2 receptor levels were decreased in both mitochondrial and cytosol 
fractions upon NRG1 Type I treatments.  Schwann cell cultures were treated with vehicle or 
10 ng/ml NRG1 Type I for 1 hour and protein lysates were collected and separated by SDS-
PAGE.  HSP60 was a marker for mitochondrial fraction and β-actin served as a loading control. 
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Figure 4.3.4: NRG1 Type I-induced activation of p42/p44 MAPK pathway decreased in a 
time-dependent manner in cultured primary Schwann cells.  Schwann cell cultures were 
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treated with vehicle or 10 ng/ml NRG1 Type I for 1, 4, and 24 hours and protein lysates were 
collected and separated by SDS-PAGE.  Immunoblot analysis were quantified, activities of 
p42/p44 MAPK were expressed as a fold of the levels in non-treated cells. 
 
4.4. Conclusions 
In summary, our data support that diabetes may alter Erb B2 signaling in peripheral nerves 
by altering the balance in NRG1 isoform expression and downregulating the expression of erbin, 
an adapter protein that can function as a negative regulator of p42/p44 MAPK signaling via Erb 
B2 receptors.  Though a limitation of our study is that we cannot ascertain if changes in NRG1 
isoforms are necessary or sufficient to contribute to DPN, altered signaling through the NRG1-
Erb B2 ligand-receptor pair may contribute to dysfunction of both myelinated and unmyelinated 
fibers since diabetic mice treated with Erb B2 receptor inhibitor erlotinib exhibited an 
improvement in both mechanical and thermal sensitivity.  Given the complex role of neuregulins 
in controlling both myelination and demyelination, these data suggest that an altered 
neuregulinism may contribute to myelin pathologies that develop in human DPN. 
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